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ABSTRACT OF DISSERTATION 
 
DAPK3 Suppresses Mammary Acini Morphogenesis and is Required for Mouse Development 
 
by 
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Doctor of Philosophy in Biological and Biomedical Sciences 
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Washington University in Saint Louis, 2014 
Dr. David Piwnica-Worms, Chairperson 
 
Over the past decade several lines of research have indicated that DAPK3, a member of the 
serine/threonine death associated protein kinase (DAPK) family, plays an important role in 
various signaling pathways important to tissue homeostasis and mammalian biology. Considered 
to be a putative tumor suppressor, the molecular mechanisms by which DAPK3 exerts its tumor 
suppressor functions are not fully understood. Furthermore, unlike other DAPK family members, 
DAPK3 has received little attention regarding its physiological roles in vivo due to the lack of 
knockout animals. To address these gaps in our fundamental understanding of DAPK3 we 
utilized the MCF10A 3D tumorigenesis model in vitro and generated a constitutive DAPK3 
knockout mouse. Using the MCF10A 3D morphogenesis model we identified that loss of 
DAPK3 through lenti-viral mediated knockdown accelerates MCF10A acini proliferation and 
apoptosis while maintaining acini polarity relative to negative control. Furthermore, depletion of 
DAPK3 leads to enhanced growth factor–dependent mTOR activation and enlarged DAPK3 
structures are uniquely sensitive to low doses of rapamycin treatment compared to negative 
control. Simultaneous knockdown of RAPTOR (a key mTORC1 component) rescues the 
ix 
 
augmented acinar size in DAPK3 depleted structures indicating an epistatic interaction.  To 
identify the overall physiological contribution of DAPK3 we generated a constitutive DAPK3 
knockout mouse using a gene trap embryonic stem cell line from the International Gene Trap 
Consortium. Described herein we have identified that DAPK3 is vital for early mouse 
development and that the Dapk3 promoter exhibits spatio-temporal activity in the developing 
heart and nervous system in addition to the gastrointestinal myenteric plexus of adult mice. 
Importantly, our data suggests that DAPK3 is expressed in the breast epithelia of adult mice and 
that potential ablation of DAPK3 expression can facilitate the development of breast cancer as 
observed in primary patient biopsies.  Our studies shed light on the growth inhibitory 
mechanisms of DAPK3 and provide direct evidence that DAPK3 plays an underappreciated role 
in mouse development, warranting further studies.  
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CHAPTER 1: INTRODUCTION 
1.1 Death-associated protein kinase family (DAPK) 
The death-associated protein kinase (DAPK) family is a relatively novel group of serine/ 
threonine kinases characterized by shared kinase domain homology as well as a pronounced cell 
death phenotypes upon overexpression.  DAPK1, the prototypical family member, was first 
identified as a positive regulator of interferon gamma-induced cell death in HeLa cells using an 
anti-sense cDNA library screen (1). Additional studies indicated that the intrinsic cell death 
promoting activities of DAPK1 were dependent on its kinase activity; a characteristic soon found 
true for all DAPK family members (2). The DAPK family is phylogenetically related to the 
CaM-regulated kinases and includes 5 members: DAPK1, DAPK2 (DRP1), DAPK3 (ZIPK), 
DRAK1 (STK17A), and DRAK2 (STK17B) (Figure 1.1) (3).  In addition to the similar 
overexpression phenotypes, the family is defined by amino acid sequence homology that exists 
between each member’s N-terminal kinase domain. Despite similar kinase domains, family 
members differ drastically through the presence of additional regulatory domains. DAPK1 has a 
Ca
2
+/ CaM regulatory domain, ankyrin repeats, a cytoskeletal binding and death domain.  
DAPK2 also contains a Ca
2
+/ CaM regulator domain but lacks these additional domains similar 
to DAPK3, DRAK1 and 2.  Overall, this family has diverse roles in inflammation, stress-
response, muscle contraction, tumor suppression and cell death. 
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1.2 DAPK3  
  While DAPK1 has received the most attention regarding biochemical function and 
phenotypes, relatively little is known about DAPK3. DAPK3 shares 83% amino acid homology 
within its kinase domain but lacks the additionally regulatory domains observed in DAPK1. 
DAPK3 also contains three putative C-terminal nuclear localization signals in addition to a 
leucine zipper motif (Figure 1.1). DAPK3 was first identified as an ATF4 interaction partner 
through a yeast two-hybrid screen using respective leucine zipper domains from a mouse cDNA 
library (4). The leucine zipper domain of DAPK3 is also required for homodimerization. 
Currently no clear regulation of DAPK3 endogenous activity has been determined.  However, 
upon overexpression, DAPK3 and DAPK1 interact via their kinase domains resulting in trans- 
phosphorylation of DAPK3 by DAPK1 at various sites. This DAPK1-DAPK3 signaling cascade 
is required for the activation of a translational inhibitory gene expression program (5).  
  Functional DAPK3 studies are limited by the lack of a knockout mouse (constitutive or 
conditional knockout).  One group reportedly attempted to generate a conditional DAPK3 
knockout mouse but admitted its failure through personal communications (Hagerty L & 
Haystead T. Unpublished Thesis Dissertation, 2007).  Commonly used model systems such as 
Caenorhabditis elegans, Saccharomyces cerevisiae, and Drosophila melanogaster lack clear 
DAPK3 orthologues, thereby hindering traditional genetic interrogation.  Uncovering the 
physiological contributions of DAPK3 is crucial to understanding the relevancy of previous 
clinical and basic research observations. Furthermore, DAPK1 and DAPK3 inhibitors are 
currently under development for use in smooth muscle related disorders and a DAPK3 deficient 
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animal may indicate potentially deleterious phenotypes associated with loss of a functional 
DAPK3 protein (6,7). 
Further hampering the functional understanding of DAPK3, many groups have published 
conflicting reports concerning the localization and respective molecular functions of DAPK3. 
One group of research indicates that ectopically expressed DAPK3 resides mainly within the 
cytoplasm and induces membrane blebbing, cell rounding and actin filament assembly (8,9). 
DAPK3 cytoplasmic subcellular localization has also been shown to  correlate with its death 
inducing function in certain animal cell lines (3). These phenotypes have been attributed to 
DAPK3’s direct phosphorylation of myosin light chain II (MLC) (8) and/ or GTP-dependent 
RhoD-mediated  actin reorganization and actomyosin contraction (9).  An additional cytoplasmic 
function of DAPK3 involves Ca
2+
 sensitization and smooth muscle contraction that is dependent 
on DAPK3 mediated phosphorylation of MLC and inactivation of smooth muscle myosin 
phosphatase (SMMP-1M) and CPI17 (7,10).  
  Contrasting with these cytoplasmic observations, other groups have indicated a nuclear 
specific localization and subsequent molecular action of DAPK3. Upon ectopic expression of 
DAPK3 by other groups, DAPK3 was observed to display nuclear localization with a ‘speckled 
pattern’ considered to be promyelocytic leukemia oncogenic bodies (PODs) (4,11–14). 
Subsequent research indicated that DAPK3 participates in the translocation of pro-cell death 
proteins DAXX (Fas death domain-associated protein) and PAR-4 (prostate apoptosis response-
4) to PODs (13,15,16).  
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 These discrepancies regarding DAPK3 subcellular localization and resulting 
overexpression phenotypes have recently been resolved.  Through overexpression and sequence 
alignment studies in various cell lines Shoval et al revealed that ectopically expressed human and 
zebrafish DAPK3 resides in the cytoplasm while rat DAPK3 localizes specifically to the nucleus 
(17). Indeed, the majority of DAPK3 nuclear localization studies were performed using rat 
DAPK3 in established rat cell lines while cytoplasmic studies were performed using human 
DAPK3 in human cell lines such as HEK293T and HeLa. These studies shed light on additional 
questions regarding protein interaction partners. Rat DAPK3 was found to strongly interact with 
PAR-4 while human and zebrafish do not bind PAR-4. The authors also hypothesized that mouse 
DAPK3 is localized to the nucleus based upon amino acid sequence similarities but did not 
report any actual localization studies. These studies have identified a phylogenetic specific 
divergence for localization and potentially function of DAPK3 but questions still remain 
regarding the localization-dependent function of mouse DAPK3. 
1.3 DAPK3 & Cancer   
 Two clear lines of research regarding DAPK3 related phenotypes exist: cell death and 
cytoskeletal regulation.  From a fundamental cell biology perspective these cell death or ‘tumor 
suppressive’ observations are mainly inferred through ectopic expression of DAPK3 and other 
DAPK family members.  Specifically, members of the DAPK family are considered to be 
involved in ‘apoptotic’ and/ or autophagy-related cell death programs with varying degrees of 
experimental support for each member.  However, despite various reports regarding the role of 
DAPK members in autophagy (via LC3 punctate structures or processing) no additional 
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autophagy –rescue experiments (chemical or genetic)  have been published that would satisfy the 
official Nomenclature Committee on Cell Death of 2012 (18). Additionally, notable 
discrepancies regarding their role in apoptosis exist, largely due to the old-world 
misinterpretation of ‘apoptotic’ cells displaying ‘characteristic apoptotic’ morphology. These 
‘apoptotic morphologies’ include membrane blebbing (commonly observed in dividing, mobile 
and apoptotic cells) (19), loss of membrane integrity (20) and DNA condensation or 
fragmentation (sub G1 content).  Ectopic overexpression of DAPK1 or DAPK3 does not lead to 
caspase-dependent apoptosis as seen by the lack of apoptotic caspase activation and PARP 
cleavage, but DNA degradation has been observed (21–23). Collectively, these results suggest 
that overexpression of DAPK1/ DAPK3 causes a form of cell death similar to caspase-
independent or necrotic cell death as cells detach and lose membrane integrity. Since the 
majority of exploratory DAPK-mediated cell death experiments have occurred in the context of 
ectopic overexpression, it is possible that the observed cell death is secondary to cell detachment 
due to forced cytoskeletal contraction and rearrangement.  Indeed, it is well known that various 
members of the DAPK family participate in cytoskeletal dynamics through phosphorylation and 
direct interaction with MLC, ROCK1, RhoD, MLCK, and CPI-17 (3). However, notable 
biochemical features of anoikis as determined by the Nomenclature Committee on Cell Death of 
2012, such as caspase activation, are not observed in ectopic expression experiments.  While the 
type of cell death observed upon ectopic expression of DAPK3 remains to be determined, several 
clinical observations suggest these growth inhibitory properties are inactivated in various 
cancers.  
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  Alterations within the DAPK3 coding sequence and its expression have been observed in 
several types of cancers prompting investigation into the tumor suppressive mechanisms of 
DAPK3.  Heterozygous loss-of-function mutations were identified in various cancers that 
influenced cell survival, proliferation, aggregation and chemotherapy resistance (23).  
Additionally, reduced DAPK3 mRNA expression correlated with tumor invasion, metastasis and 
was a poor prognostic factor in a population of over 160 gastric cancer patients (24).   These 
observations are not specific to gastric cancer as knockdown of DAPK3 increases proliferation 
of various malignant cell lines in vitro (23). Abrogation of DAPK3 mRNA expression was 
shown to significantly decrease cisplatin sensitivity in lung cancer cell lines and its 
downregulation may impact overall survival of non-small cell lung cancer patients treated with 
platinum-based therapy (25).  DAPK3 is also considered a potentially novel breast cancer gene 
as recurrent DAPK3 alterations were observed in BRCA1 mutant and BRCA-1 non-mutant 
breast cancers (26).  Additionally, DAPK3 has been shown to interact with and/ or phosphorylate 
various proteins in vitro that are  involved in cancer including ATF4, AATF, Daxx, Par-4, 
STAT3, NLK, and AR (4,14,27–32). These basic research and clinical observations have spurred 
further interest into defining the key molecular pathways regulated by DAPK3 in the hopes of 
identifying novel anti-cancer therapies.   
  These observations are not unique to DAPK3 and are similarly observed for DAPK1, the 
most well characterized tumor suppressor of the DAPK family. Originally identified as a 
potential mediator of interferon gamma -induced cell death, DAPK1 has since been regarded as a 
bona fide tumor suppressor in large part through the efforts of the Dr. Adi Kimchi Lab (1). It was 
first posited that DAPK1 is a tumor suppressor after identification of non-existent DAPK1 
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protein expression in various human cancer cell lines that could be partially restored by DNA 
demethylation (33).  Since these initial studies it has been shown that DAPK1 ectopic expression 
can reduce metastasis and soft agar colony formation (34). Others have shown that DAPK1 
overexpression activates p19ARF/p53 dependent ‘apoptosis’ in a kinase-dependent manner and 
that DAPK1 is required for p53 induction following oncogene activation (via overexpression of 
c-Myc and E2F-1) (35).  Another group showed that DAPK1 mRNA expression is induced upon 
DNA damage in a p53-dependent manner (36).  Indeed, it appears that DAPK1 is mainly 
regulated through epigenetic repression of DAPK1 mRNA expression via promoter 
hypermethylation. The DAPK1 promoter is hypermethylated in various cancers including lung, 
bladder, head and neck, kidney, breast and B cell malignancies relative to normal tissues (37–
42). Interestingly, despite these hypermethylation observations, several studies have shown that 
DAPK1 protein remains largely unaffected in certain patient cohorts (42). Given that no loss-of-
function mutations have been reported for DAPK1, research performed to date indicates mRNA 
expression as a crucial means of regulating DAPK1 and potentially other DAPK members such 
as DAPK3.  
1.4 The mTOR Pathway 
My research has identified DAPK3 mediated inhibition of the mTOR pathway as a novel 
growth inhibitory or tumor suppressive mechanism and further discussion requires an 
introduction to the mTOR pathway.  
The ‘mechanistic target of rapamycin’ or mTOR protein kinase was initially identified as 
a crucial mediator of the profound anti-proliferative effects exerted by rapamycin, a macrolide 
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produced by Streptomyces hygroscopicus. mTOR was first purified and determined to be a 
functional target of  rapamycin in  the early 1990s (43–45). Since its initial discovery the mTOR 
pathway has been implicated as a major regulator of cellular and tissue energy metabolism, 
growth  and proliferation (46). As a member of the phosphoinositide 3-kinase (PI3K)-related 
kinase family, mTOR is considered to be an atypical serine/ threonine non-lipid protein kinase. 
mTOR interacts with a variety of protein binding partners and ultimately forms two distinct and 
massive protein complexes (mTORC1 and mTORC2) that respond to and regulate a diverse 
array of upstream and downstream signaling (Figure 1.2). Both complexes respond to a variety 
of stimuli and regulate a number of key processes including cell growth, metabolism autophagy 
and many other biologic programs. 
The large mTORC1 and mTORC2 complexes are composed of a unique set of interaction 
partners that help regulate the diversity of functions controlled by the mTOR pathways.  
mTORC1 is comprised of six known subunits including the catalytic mTOR subunit, mammalian 
lethal with sec-12 protein 9 (mLST8/ GβL) (47), DEP domain containing mTOR-interacting 
protein (DEPTOR) (48), the scaffold protein complex Tti1/Tel2 (31), regulatory-associated 
protein of mammalian target of rapamycin (raptor) (49,50), and proline-rich Akt substrate 40 
kDa (PRAS40) (51–54).  Similarly, the relatively rapamycin insensitive mTORC2 shares mTOR, 
mLST8 (55), DEPTOR (48) and Tti1/ Tel2 (31) but differs through interactions with rapamycin-
insensitive companion of mTOR (rictor) (55,56), mammalian stress-activated map kinase-
interacting protein 1 (mSin1) (57,58) and protein observed with rictor 1 and 2 (protor1/2) 
(52,59,60). Rapamycin directly inhibits mTOR when it is associated with mTORC1 through 
allosteric kinase inhibition (61–63) and/ or structural disruption (49,64).  
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mTORC1 is the most well understood of the two mTOR complexes and it responds to a 
diversity of signals including growth factors, stress, energy status, oxygen and amino acids. 
Using the epidermal growth factor (EGF) pathway as a representative example, mTORC1 is 
activated by two major signaling pathways downstream of the EGF receptor (EGFR): PI3K-AKT 
and RAS-ERK (65). Extracellular binding of EGF to the receptor tyrosine kinase EGFR induces 
receptor homo- and/or heterodimerization of EGFR monomers resulting in cytoplasmic trans- 
and/ or autophosphorylation and subsequent activation of PI3K-AKT and RAS-ERK pathways. 
The initial stages of activation for both pathways involve proximity-based activation through 
phosphatidylinositol-phosphoinositide dependent kinase 1 (PDPK1) (66) and growth factor 
receptor-bound protein 2 (GRB2) -son of sevenless (SOS) for AKT and RAS-ERK, respectively 
(67). The effector components of both pathways ultimately converge on phosphorylation and 
inhibition of the tuberous sclerosis complex (TSC) which is made up of TSC1, TSC2 and Tre2-
Bub2-Cdc16 (TBC) 1 domain family member 7 (TBC1D7). This effectively activates mTORC1 
through an as of yet not well understood mechanism (68). 
Once activated, downstream components of mTORC1 signaling regulate cell growth (cell 
mass), macromolecular biosynthesis, autophagy, and cell cycle progression.  mTORC1 
regulation of protein synthesis is the most fundamental and well understood mechanism by 
which mTORC1 influences these multiple cell processes. Once activated, mTORC1 directly 
phosphorylates two key protein translational and synthesis regulators: eukaryotic initiation factor 
4E-binding protein 1 (4E-BP1) and S6 kinase (S6K) (69). Overall, regulation of these 
components ultimately controls translation of key transcripts involved in ribosome biogenesis, 
cell cycle, anti-apoptosis, metastasis, angiogenesis and glycolysis. mTORC1 mediated 
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phosphorylation of 4E-BP1 prevents it from inhibiting the assembly of eIF4E at the 5’ mRNA 
cap thereby effectively facilitating the formation of the pre-initiation complex at the ribosome. 
mTORC1 initiates S6K activation through phosphorylation of T389 which creates a docking site 
for PDPK1 allowing it to phosphorylate S6K at T229 (69). Once activated by mTORC1, S6K 
phosphorylates a variety of translational regulator substrates including eukaryotic elongation 
factor 2 kinase (eEF2K), S6 Aly/ REF-like target (SKAR) and ribosomal protein S6 (S6) which 
ultimately facilitates translation initiation and elongation (70). An increase in the translation of 
cell cycle progression, ribosomal protein and translational elongation factor mRNA transcripts 
correlates with the phosphorylation of S6 (71). Interestingly, primary mouse embryonic 
fibroblasts (MEFs) produced from mice with homozygous knock-in S->A mutations at key S6 
phosphorylation sites, display decreased cell size but augmented protein synthesis and cell 
division (72). Moreover, MEFs produced from mice devoid of all three 4E-BPs (1-3) display 
increased proliferation (73). While these observations suggest S6 positively regulates cell growth 
and 4E-BPs negatively regulate proliferation, it is generally accepted that phosphorylation of 4E-
BP1 and S6K-S6 serve as representative mTORC1 specific markers. And, that these markers are 
indicative of other mTORC1 specific translational programs that might be directly involved in 
the regulation of proliferation and cell growth, independent of these markers.   Indeed, it is 
anticipated that phospho-S6 and phospho-4E-BP1 will serve as pharmacodynamic markers for 
mTORC1 activity in oncology clinical trials (74). 
While much is known about mTORC1, only a handful of studies in the past 10 years have 
shed light on the mTORC2 pathway. mTORC2 integrates signals mainly from growth factors to 
control cell metabolism, cytoskeletal organization and cell survival. mTORC2 activates several 
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members of the AGC subfamily of kinases (AKT, and SGK1 or serum-and glucocorticoid-
induced protein kinase 1) thereby regulating the phosphorylation of forkhead box O1/3a 
(FoxO1/3a) and the subsequent transcription of genes required for metabolism, cell cycle arrest 
and apoptosis (75,76).  mTORC2 also activates protein kinase C-α (PKC-α) thereby playing a 
pivotal role in cell shape and actin cytoskeleton dynamics (55,56). 
1.5 mTOR & Cancer 
 Pre-clinical and clinical observations indicate that mTORC1 and 2 are crucial for the 
development of cancer and as such have become attractive anti-cancer targets. Activating 
mutations in PI3K or deletion of the PI3K inhibitory protein, phosphatase and tensin homologue 
(PTEN), are commonly observed in human cancer resulting in hyperactivation of mTOR and 
AKT (77).  Several negative regulators of the mTOR pathway are bona fide tumor suppressors 
and are widely deregulated in various human cancers. Inherited mutations in TSC1 and 2 causes 
tuberous sclerosis, a familial cancer that results in hamartomas and benign tumors in various 
organs (78). Conditional loss of TSC1 in the liver of mice results in hyperactive mTORC1 
signaling and hepatocellular carcinoma, the development of which recapitulates human liver 
carcinogenesis (79).  Another familial cancer syndrome, Peutz Jegher’s syndrome, is caused by 
the loss of the tumor suppressor liver kinase B1 (LKB1) which results in the development of 
intestinal polyps and dramatically increases a patients risk for other cancers (80). LKB1 is 
deleted in 58% of lung cancers and is known to be a major negative regulator of mTORC1 
signaling through AMPK mediated activation of the TSC complex (81). 
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  Given these profound clinical oncology observations, mTOR inhibition has become a key 
therapeutic focus for anti-cancer therapies including combination therapy.  This is supported by 
two recent studies that determined several tumors develop resistance to PI3K and BRAF 
inhibitors through mTORC1 signaling (82,83). Over the past decade rapamycin and several next-
generation mTORC-specific inhibitors (rapalogues and mTOR kinase inhibitors) have witnessed 
improved clinical safety profiles but limited clinical efficacy (74).   These targeted therapies 
have failed due to activation of compensatory mechanisms and partial inhibition of the 
mTORC2-AKT pathway (74). Interestingly, out of 750 human cancer samples only 3 mTOR 
activating mutations with functional significance have been identified (84). Indeed, many 
regulators of the mTORC1 pathway that promote growth factor-independent activation of 
mTORC1 are upregulated in 80% of human cancers (85). Collectively, this indicates that 
alternative strategies to effectively inhibiting the mTOR pathway are required  
  While many of the major regulators of the mTOR pathway have been elucidated, new 
regulators are continually being identified which will undoubtedly shed light on the complexities 
of the mTOR pathway, its many negative feedback loops and potentially new anti-cancer 
therapeutic targets.  Taking a different approach, we hypothesize that rather than therapeutically 
inhibiting mTOR, an alternative strategy might include supporting the negative regulation of 
intrinsic mTOR-suppressive pathways. 
1.6 DAPK and mTOR Pathway Interactions 
  As discussed above, the mTOR pathway is a critical regulator of various pathways found 
to be influenced by the DAPK family including proliferation, ‘autophagy’, survival, cell death 
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and cell cycle regulation. Interestingly, several members of the DAPK tumor suppressor family 
are known to regulate translation and regulate or be regulated by the mTOR pathway.  Recent 
work has uncovered conflicting roles with regards to DAPK1-mediated regulation of the mTOR 
pathway. One group revealed that DAPK1 positively regulates mTOR activity through disruption 
of TSC1-TSC2 interactions (86). Another group revealed that DAPK1 negatively regulates 
protein translation through an inhibitory phosphorylation at S235/236 of S6 (87). However, 
research by Roux et al. revealed that phosphorylation of S235/236 on S6 by RSK actually 
promotes translation through enhanced assembly of the translational pre-initiation complex (88).  
DRAK2 was shown to phosphorylate S6K in vitro and play a functionally significant role in islet 
cell apoptosis (89). Overall, while some precedent exists, more work is required to identify and 
understand the functional connections between the DAPK family and mTOR regulation.  
1.7 Three-Dimensional Cell Culture as a Powerful Model of Breast 
Cancer for Elucidating Novel DAPK3 Functions 
It is clear that further research regarding the tumor suppressive functions of DAPK3 is 
warranted. Specifically, little is known about the functional tumor suppressive mechanisms 
regulated by DAPK3. Research on DAPK3 is further hampered by the lack of reliable 
immunohistochemical and immunofluorescence antibodies that can specifically recognize 
endogenous levels of mouse or human DAPK3 protein. These limitations are exacerbated by the 
lack of a knockout mouse model as well as inadequate cell culture models that cannot 
recapitulate the physiological context of tissue development or carcinogenesis.  
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Given these setbacks we have utilized a well-established three-dimensional (3D) in vitro 
epithelial tumor system that has been extensively used by other groups to study tumor 
suppressors and oncogenes. Studying tumor suppressors, such as DAPK3, in two-dimensional 
(2D) cell culture omits many of the complex external factors that are crucial to tissue 
homeostasis and carcinogenesis. Culturing cancer cells in or on an extracellular matrix (ECM) 
such as Matrigel (a protein mixture collected from Engelbreth-Holm-Swarm mouse sarcoma 
cells) or collagen supports the development of cell spheroids that closely resemble the 
architecture of glandular epithelial structures (90). 3D epithelial tumor structures form through 
coordinated series of biochemically-regulated events that are commonly deregulated in cancer 
including polarization, proliferation, survival, invasion, and apoptosis (Figure 1.3 A). Examining 
the relative contribution of tumor suppressor and oncogenes to the morphogenic phenotypes 
observed in 3D tumor systems serves as an accurate and approachable model for studying 
histopathological idiosyncrasies observed in human epithelial cancers in vivo. Furthermore, each 
structure represents a simplified tumor that can be studied and quantified in a relatively high 
throughput manner. Given the financial constraints of the current scientific research budget, the 
variability and still costly mouse models of cancer, 3D in vitro tumor systems are a highly 
attractive model for current basic cancer research. 
One of the most well characterized 3D epithelial tumor systems utilizes the non-
transformed, immortalized breast epithelial MCF10A cell line.  When seeded as a single cell 
suspension atop solidified Matrigel, MCF10A cells eventually develop in to hollow acinar 
structures that cease to proliferate after 2 weeks (Figure 1.3 A). These structures undergo a 
coordinated series of biochemical and phenotypic processes and mimic true mammary acini 
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development. Early in the development of these hollow acini apical-basolateral cell polarity is 
established. After 5-6 days a population of cells loses contact with the ECM and eventually 
undergoes apoptosis. Cells that maintain contact with the ECM exhibit survival signaling 
through AKT and continue to proliferate. As the internal cells overcome pro-survival autophagy, 
they begin to undergo apoptosis and form a hollow lumen that closely resembles the glandular 
architecture seen in the human breast (91,92). This system allows dissection of the biochemical 
pathways and the respective functional contributions of novel regulatory proteins to the well-
established 3D phenotypes of commonly deregulated oncogenic and tumor suppressive 
pathways. Indeed, the phenotypes of many cancer-associated genes have been characterized in 
detail,  including HPV16 E7, ERBB2, AKT , CSF, LKB1, c-Myc, p38,  PI3K, ERK1/2, Notch, 
STAT3, NF-κB and importantly mTORC1 (90,93–100) (Figure 1.3 B).  
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1.8 Figures 
 
Figure 1.1 mTOR pathway and its contribution to tumorigenesis. Image amended from 
Laplante, M, & Sabatini, D. 2012 (46). 
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Figure 1.2 Schematic representation of the death associated protein kinase family (DAPK). 
Various regulatory domains are highlighted in addition to the amino acid homology relative to 
DAPK1. Image amended from Bialik, S. & Kimchi A. 2006 (3).  
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Figure 1.3 MCF10A morphogenesis (A) Schematic representation of the timeline of MCF10A 
acini development when grown on Matrigel. Apical-basolateral polarity is initiated by days 4 -6 
(Lamini5 and GM130). Two clear populations of cells, proliferative and apoptotic, start to 
emerge at days 6-8. Cells that have lost contact with the Matrigel undergo apoptosis/ anoikis 
while the peripheral cells display increased AKT signaling. Eventually these structures cease to 
proliferate at day ~15 forming hollow structures. (B) The well characterized contribution of 
oncogenes to MCF10A morphogenesis.  
A
B
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CHAPTER 2: DAPK3 INHIBITION OF mTOR SIGNALING 
SUPPRESSES MAMMARY ACINI MORPHOGENESIS  
2.1 Introduction 
Death-associated protein kinase 3 (DAPK3, also known as ZIPK) is a member of the 
DAPK serine/ threonine protein kinase family and is known to regulate smooth muscle 
contraction, cell-cell adhesion, cytoskeleton dynamics, inflammation,  and cardiovascular 
functions. It is also considered a putative tumor suppressor through regulation of caspase-
dependent and -independent apoptosis, proliferation and autophagy (1).  The DAPK family 
contains 4 other members, including DAPK1, DRP-1 (DAPK-related protein 1), DRAK-1 and 
DRAK-2 (DAPK-related apoptosis-inducing protein kinase-1 and -2), which all share homology 
within their kinase domain. DAPK3 contains an N-terminal kinase domain that shares 80% 
amino acid homology with the prototypical DAPK1.  It differs from other family members by the 
presence of a C-terminal leucine zipper motif and the absence of a calmodulin-regulated (CaM) 
domain and death domain. Similar to other family members, DAPK3 is considered to be a tumor 
suppressor.  Overexpression of DAPK3 in mammalian cells results in cell death and cell cycle 
inhibition while kinase inactivating mutations along with recurrent deleterious somatic mutations 
are observed in lung and breast cancers, respectively (2-4).  Knockdown of DAPK3 increases 
proliferation of various cell lines (2).  Clinically, reduced DAPK3 mRNA correlated with 
increased tumor invasion, metastasis and overall survival in a cohort of gastric carcinoma 
patients (5). Abrogation of DAPK3 mRNA expression was shown to significantly decrease 
cisplatin sensitivity in various lung cancer cell lines and may impact overall survival of non-
small cell lung cancer patients treated with platinum-based therapy (6). DAPK3 is also 
considered a potentially novel breast cancer gene as recurrent DAPK3 alterations were observed 
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in BRCA1 mutant and BRCA-1 non-mutant breast cancers (3). Additionally, human DAPK3 
regulates a variety of signaling pathways commonly deregulated in cancer. For example, DAPK3 
negatively regulates the canonical Wnt/ β-catenin pathway by disrupting the interaction between 
Nemo-like kinase (NLK) and T-cell Factor 4 (TCF4) in colon cancer cell lines (7). DAPK3 
regulates androgen receptor-mediated transcription via ubiquitination and degradation of AR in 
various cancer cell lines (8).  DAPK3 also interacts with and/ or phosphorylated various cancer-
associated proteins in vitro, including ATF4, AATF, Daxx, Par-4 and STAT-3 (4,9-12). 
 Despite these in vitro and clinical observations, the full physiological significance of 
DAPK3 is not well understood.  Compared to the prototypical DAPK family member DAPK1, 
relatively little is known about the functional tumor suppressive mechanisms regulated by 
DAPK3.  These limitations are potentially exacerbated by the lack of a knockout mouse model as 
well as inadequate cell culture models that cannot recapitulate the physiological context of tissue 
development or carcinogenesis.  
  3-dimensional (3D) in vitro tumor systems provide the ability to functionally investigate 
the contribution of tumor suppressors and oncogenes to the complex development and 
architecture of tumor spheroids (13).  Given the utility of 3D tumor systems and the clinically 
observed mutations of DAPK3 in breast cancer (3), we chose to further explore the functional 
significance of DAPK3 in a MCF10A 3D morphogenesis model.  When grown on an 
extracellular enriched matrix (Matrigel), the immortalized MCF10A epithelial cell line forms 
hollow spheroids that undergo a regulated and coordinated series of events similar to developing 
mammary acini (14).  This model has been used to investigate the contribution of loss-of-
function (LOF) alterations to acini development and early events in tumor formation.  
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 Herein, we describe the functional significance of DAPK3 in MCF10A acini 
morphogenesis. We have identified that DAPK3 negatively regulates MCF10A morphogenesis 
through a mTORC1-S6K1-S6 pathway. We also identified that DAPK3 is downregulated in 
aggressive breast cancer relative to less aggressive and normal patient samples.   
2.2 Materials & Methods 
Cell culture and reagents 
MCF10A and 293T cells were obtained from the American Type Culture Collection. MCF10A 
cells were cultured as described elsewhere (14) and 293T were cultured in DMEM supplemented 
with 10%FBS and L-glutamine. 3D morphogenesis assays were conducted as described 
elsewhere (14).  
Plasmids and viral production 
For DAPK3 overexpression, the DAPK3 ORF was PCR amplified (from Addgene plasmid 
23436) and subcloned into pLVX-IRES-Hyg (Clonetech). PCR primers, forward: 5’- 
GAGAGACTCGAGGCCACCATGTCCACGTTCAGGCAGGAG, and reverse: 5’- 
GAGAGAGGATCCTTACTAGCGCAGCCCGCACTCCACGCCCTGC, were used to create 
the restriction enzyme sites XhoI and BamHI (in bold) that allowed for ligation into the 
corresponding sites in pLVX-IRES-Hyg. For HRas
V12
 overexpression, HRas
V12
 was amplified 
and subcloned into pLVX-IRES-Hyg. PCR primers, forward: 5’- 
GAGAGACTCGAGGCCACCATGACGGAATATAAGCTGGTGGTGGTGG, and reverse: 5’- 
GAGAGAGGATCCTTATCAGGAGAGCACACACTTGCAGCTCATG, were used to create 
the restriction enzyme sites XhoI and BamHI (in bold) that allowed for ligation into the 
corresponding sites in pLVX-IRES-Hyg.  
 
 
31 
 
pLKO.1-puro constructs obtained from the Genome Institute at Washington University were 
used for RNA interference (RNAi) against DAPK3. Sequences for the short hairpin RNAs are: 
5’- CGTTCACTACCTGCACTCTAA (herein referred to as sh1), 5’-
CCCAAGCGGAGAATGACCATT (herein referred to as sh2) and shNeg (15). For lentiviral 
production, 8 x 10
5
 293T cells were co-transfected with pCMV-VSV-G, pCMVΔR8.2, and 
pLKO.1-puro constructs using Fugene 6 (Promega). Forty-eight hours post-transfection, viral 
supernatants were collected. PLKO.1 hygro shRNA constructs against Rictor and Raptor were 
generated by subcloning hygromycin in place of puromycin within the pLKO.1-constructs. 
Immunofluorescence and confocal microscopy 
MCF10A acini were grown in 8 well chamberslides and at the indicated time point were fixed 
with 4% paraformaldehyde (PFA) in PBS for 30 minutes at room temperature. Slides were 
washed three times (15 minutes each wash) at room temperature in 100 mM glycine in PBS and 
subsequently permeabilized with 0.05% Tween 20 in PBS, pH 7.4 for 20 minutes. Fixed acini 
were blocked in IF buffer (0.2% Triton X-100, 0.1% BSA-radioimmunoassay grade from Sigma 
Aldrich, 0.05% Tween 20 in PBS, pH 7.4) and 10% goat serum for 1.5 hours at room 
temperature and then blocked in secondary block containing IF buffer + 10% goat serum + 
20ug/mL goat anti-mouse IgG F(ab’)2 fragment specific (Jackson ImmunoResearch, Cat. 115-
006-006)  in a humidified chamber for 30 minutes. Fixed acini were then stained with 1:100 
primary antibody in IF buffer + 10% goat serum + 20ug/mL goat anti-mouse IgG F(ab’)2. 
Primary antibodies were as follows: rabbit anti-Ki67 (Cell Signaling, 9129), rabbit-anti cleaved 
caspase 3 (Cell Signaling, 9579), rat anti-integrin alpha 6 (Millipore, MAB1378) and rabbit anti-
giantin (Covance, PRB-114C). The following day the slides were washed three times in IF buffer 
for 20 minutes each and incubated with a secondary antibody (conjugated to Alexa Fluor 488 or 
 
 
32 
 
594) diluted in IF buffer +10% goat serum for 40 minutes at room temperature in a humidified 
chamber. Slides were washed three times in IF buffer for 20 minutes each and then incubated 
with 1 µM TOPRO3 iodide (Molecular Probes) in PBS for 10 minutes at room temperature in a 
humidified chamber. Slides were then washed with PBS once for 10 minutes and mounted with 
Prolong Antifade mounting medium (Molecular Probes). Images were obtained using an 
Olympus FV-500 confocal microscope with a 20X water objective. Images were processed using 
the Olympus FLUOVIEW Ver.2.1a Viewer and ImageJ software. For Ki67 and cleaved caspase 
3 evaluations, a total of 10 fields with at least 4 acini per field were acquired and then analyzed 
as indicated. 
Acini diameter quantification and statistics 
Size analysis was performed using a haemocytometer and ImageJ software for each brightfield 
image. At least 50 acini from a single field of view were analyzed for acini diameter. The 
Student’s t-test was used for statistical analysis.  
Immunoblotting   
Harvested cells were re-suspended and sonicated in radioimmunoprecipitation assay (RIPA) 
buffer (50mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic 
acid) containing protease and phosphatase inhibitors (1mM phenylmethylsulfonyl fluoride 
(PMSF), 0.4 U/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM β–glycerophosphate, 
0.1 mM NaF, 0.1 mM NaVO4). Proteins (30 to 80 g) were fractionated on 10% Tris-HCl, 
Criterion Precast Gel (Bio-Rad). Separated proteins were transferred onto polyvinylidene 
difluoride (PVDF) membranes (Millipore), and probed with the following antibodies: rabbit anti-
DAPK3/ ZIPK (abcam, ab51602 and for K42A Cell Signaling, 2928)), rabbit anti-β catenin 
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(Santa Cruz, H-102), mouse anti-phospho-p70/p85 (Cell Signaling, 9206),  rabbit anti-p70/p85 
(Cell Signaling, 2708), rabbit anti-phospho-pS6 (Cell Signaling, 2215), mouse anti-S6 (Cell 
Signaling, 2317), rabbit anti-GAPDH (Sigma-Aldrich, G9545), rabbit anti-phospho-T308 AKT 
(Cell Signaling, 9275), mouse anti-AKT (Cell Signaling, 2920), rabbit anti-phospho-ERK (Cell 
Signaling, 4370), rabbit anti-Actin (Sigma-Aldrich, A2066), mouse anti-RAPTOR (Santa Cruz, 
sc-81537) and rabbit anti-RICTOR (Cell Signaling, 2140).  Secondary horseradish peroxidase-
conjugated anti-rabbit or anti-mouse antibodies (Sigma-Aldrich) were added and ECL Western 
Blotting Substrate or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Scientific) were used to visualize protein bands. 
 
Soft agar assay 
 MCF10A cells were first infected with HRas
V12
, shNeg, sh1, or sh2 expressing lentivirus and 
then selected in puromycin (1 g/ml) until canaries were dead. Following drug selection, 1 x 104 
stables cells were seeded in 6-well plates, and the cells were fed with fresh media twice a week. 
After 3 weeks, plates were stained with crystal violet overnight, washed and colonies were 
manually counted. 
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2.3 Results 
DAPK3 depletion augments acini morphogenesis 
To further investigate additional mechanisms by which DAPK3 exerts tumor suppressive 
functions, we performed stable shRNA knockdown of DAPK3 in MCF10A cells grown on 
Matrigel using two independent hairpins.  As discussed previously, this model permits 
interrogation of acini architecture development, which undergoes a series of highly conserved 
temporally-concerted biochemical and phenotypic events. First, loss of DAPK3 significantly 
enhances acini diameter by approximately 37+10 % as compared to negative control shRNA at 
day 8 (Figure 1A, B).  Diameter enhancement was observed as early as day 4 and continued to 
increase over time while the negative control plateaued at later time points. Interestingly, 
DAPK3 depletion does not enhance anchorage independent growth of MCF10A cells growth in 
soft agar (Figure 2).  
Loss of DAPK3 results in enhanced acini proliferation and apoptosis 
It has been well established that size and morphogenesis of MCF10A acini is dependent 
on coordinated proliferation and apoptotic programs. To understand which of these processes 
was perturbed in DAPK3 knockdown structures, we performed confocal immunofluorescence 
microscopy on acini structures.  DAPK3-depleted structures contained, on average, significantly 
more Ki67+ cells compared to negative control (Figure 3). Interestingly, loss of DAPK3 also 
augmented cleaved caspase 3-positive acini relative to negative control (Figure 4). This was 
additionally confirmed by ethidium bromide uptake in live MCF10A acini which also indicated a 
significant increase in cell death in DAPK3 depleted structures (Figure 5). Thus, while there was 
a net increase in acinar size, we hypothesize that as the shDAPK3 structures underwent 
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hyperproliferation, more cells lost contact with the ECM and as a result underwent apoptosis, a 
phenomenon which has been observed elsewhere (16).  Of note, we did not observe any 
alterations in acini apical or basolateral polarity as indicated by proper localization of giantin and 
integrin α6, respectively (Figure 6 A, B). 
DAPK3 overexpression disrupts normal acini formation 
To determine if DAPK3 overexpression impacts acinar morphogenesis, we stably 
overexpressed DAPK3 fused to GFP in MCF10A cells that were subsequently grown in 3D. 
Despite a large degree of toxicity observed in the packaging cells, we were able to achieve stable 
populations of MCF10A cells that survived selection. However, we were not able to achieve high 
overexpression of DAPK3 most likely due to overexpression toxicities in both target and 
packaging cells that are commonly observed across several cell types (2,17). Additionally, this 
expression was lost over time indicating negative selection for sustained high level expression of 
DAPK3.  Given these technical challenges, structures that maintained overexpression (as 
indicated by GFP fluorescence) displayed a dramatic and significant decrease in structure size 
compared to empty-GFP vector alone (Figure 7A, B). We also attempted to determine if this 
decrease in size was dependent on DAPK3 kinase activity but we were unable to achieve stable 
overexpression of a previously characterized kinase deficient point mutant (K42A) fused to GFP 
(data not shown).   However, stable overexpression of an unfused K42A mutant exhibited 
microscopic colony growth in soft agar highly similar to negative control, while a significant 
decrease was observed in stable cells overexpressing wildtype DAPK3 (Figure 8), consistent 
with growth inhibiting-dependence on kinase activity. 
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DAPK3 negatively regulates mTOR-S6K-S6 signaling with no effect on ERK 
or AKT activation 
To identify the pathways functionally regulated by DAPK3 we initially compared our 
structural phenotypes to that reported in the literature. Several groups have shown that enhanced 
mTOR activity leads to acini with similar abnormalities observed upon loss of DAPK3 (18-20). 
Indeed, upon loss of DAPK3 in MCF10A cells grown in 2D culture we observed an increase in 
phosphorylation of S6 (P-S6) and both p70 and p85 S6K1 isoforms (herein referred to as P-S6K) 
when stimulated with EGF or insulin (Figure 9). We additionally observed an increase in P-S6 
from MCF10A cells depleted of DAPK3 that were grown in 3D for 6 days (Figure 10). Of note, 
we did not observe an increase in ERK or AKT signaling (Figure 10)  
Loss of DAPK3 influences proper acini morphogenesis through mTORC1 
To further confirm that this enhanced mTOR signaling was functionally relevant, we 
treated established negative control and DAPK3-depleted acini with 100 nM rapamycin once 
starting at day 4. 4 days later we observed that rapamycin had no significant effect on the 
diameter of the negative control. However, acini stably transduced with both independent 
DAPK3 hairpins displayed a significant sensitivity to rapamycin treatment (Figure 11 A).  
Additionally, established shDAPK3 acini treated with increasing concentrations (100 nM, 10 µM 
and 50 µM) of the PI3K inhibitor LY294002 displayed similar increased sensitivity to the drug 
compared to negative control (Figure 11B). 
To further delineate how DAPK3 regulates mTOR for proper acini morphogenesis, we 
stably knocked down DAPK3 and RICTOR or RAPTOR using previously reported hairpins (21). 
Interestingly, we observed that loss of DAPK3 and RAPTOR blunted the increased acini size 
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whereas loss of RICTOR did not rescue the phenotype (Figure 12A). Additionally, loss of 
RAPTOR by itself had a profound impact on acini formation whereas knockdown of RICTOR 
did not.  
Clinically observed down regulation of DAPK3 mRNA 
Finally, we wanted to confirm that our cell culture observations mimic that seen in actual 
patients using the Oncomine database (www.oncomine.org).  Indeed, DAPK3 mRNA is 
significantly downregulated in ductal breast carcinoma in situ (DCIS) and invasive ductal breast 
versus normal breast and DCIS controls, respectively (Figure 13 A, B).  DAPK3 mRNA is also 
significantly downregulated in pancreatic adenocarcinoma as well as melanoma versus normal 
controls (Figure 13 C, D). 
2.4 Discussion 
Herein we have shown that loss of DAPK3 leads to increased acini size, enhanced acini 
proliferation and apoptosis without disrupting apical-basolateral polarity. Conversely, stable 
overexpression of DAPK3 inhibits acini morphogenesis and is relatively toxic to cells.  Loss of 
DAPK3 augments acini morphogenesis through mTOR-S6 signaling. This regulation appears to 
be downstream of the mTOR pathway as loss of DAPK3 enhanced S6K-S6 phosphorylation, but 
not ERK or AKT. Furthermore, this regulation is specific to mTORC1 and not mTORC2 as only 
loss of RAPTOR (and not RICTOR) partially rescues the augmented acinar morphogenesis 
observed upon loss of DAPK3.  Collectively, our data reveal a novel tumor suppressive 
mechanism for DAPK3 through its inhibition of mTOR-S6K-S6 signaling (Figure 12B)  
It is well known that the mTOR pathway plays an important role in cancer cell growth, 
survival and proliferation (22). As such, activation of the pathway is controlled by several 
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upstream tumor suppressors including LKB1 and NF1 (23,24). mTOR is the fundamental 
catalytic component of two distinct complexes,  rapamycin-sensitive mTORC1 and rapamycin 
insentitive-mTORC2, each of which is composed of distinct protein complexes that alter the 
protein-protein interactions, subcellular localization, activity and substrate specificity of the 
active complex. Genetic ablation of key scaffolding proteins RAPTOR or RICTOR effectively 
prevents signaling through mTORC1 and mTORC2, respectively. Our data indicates that the 
increased acini size observed upon loss of DAPK3 is uniquely sensitive to mTORC1 inhibition. 
Indeed, mTORC1 has been shown to play a large role regulating many of the processes required 
for acini morphogenesis and thus these observations are expected.  
Interestingly, several other members of the DAPK tumor suppressor family are known to 
regulate translation and regulate or be regulated by the mTOR pathway. Conflicting reports 
reveal that DAPK1 disrupts TSC1-TSC2 association thereby enhancing mTOR activation and 
negatively regulates protein translation through an inhibitory phosphorylation at S235/236 of S6 
(25,26).  However, Roux et al. revealed RSK-dependent phosphorylation at S235/ 236 actually 
promotes translation through assembly of the translational pre-initiation complex (27).  DRAK2 
phosphorylates S6K kinase in vitro and in vivo (28).  DAPK3 is phosphorylated by DAPK1 in 
vitro and this DAPK1-DAPK3 kinase cascade has been shown to inhibit transcript-specific 
translation through phosphorylation of the ribosomal protein L13a and activation of an 
translational inhibitor complex known as the interferon-gamma activated inhibitor of translation 
(GAIT) complex (17,29). These observations along with our data implicate the DAPK family as 
important regulators of translation and mTOR signaling. 
Overall, the research presented herein indicates that suppression of mTOR-S6K-S6 
signaling by DAPK3 maintains proper acini morphogenesis and that these mechanisms 
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potentially exist in several human cancers where DAPK3 mRNA is downregulated.  Further 
studies are necessary to uncover the biochemical mechanism by which DAPK3 inhibits the 
mTOR pathway. Our data suggests that the kinase activity of DAPK3 is required and thus 
DAPK3 potentially induces an inhibitory pathway through activation of an mTOR inhibitor or 
inhibition of an mTOR activator. Interestingly, we did not observe an increase in soft agar micro-
colony growth in MCF10A stably expressing the kinase dead mutant relative to empty vector 
control. This may indicate cell line specific effects as other cell lines have previously shown a 
dominant negative effect on proliferation with this mutant (2).  
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2.5 Figures 
 
Figure 1. Loss of DAPK3 augments MCF10A acini. (A) MCF10A cells stably expressing shNeg 
or two independent DAPK3 hairpins (sh1, sh2) were cultured on Matrigel for 12 days. 
Brightfield images show representative structures at specific time points. (B) Mean diameter of 
MCF10A acini stably expressing respective hairpins at various time points. Depicted here is a 
representative of three independent experiments. Error bars indicate 95% confidence intervals. *, 
P < 0.005 relative to control.  
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Figure 2. Loss of DAPK3 expression does not promote anchorage independent growth of 
MCF10A cells. Stable MCF10A cell lines were grown in soft agar for 3 weeks. 
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Figure 3. DAPK3 depleted acini exhibit increased proliferation.  Fluorescent confocal 
microscopy analysis of acini stained for Ki67 (green) and DNA (blue). Depicted here is a 
representative of two independent experiments. Error bars indicate 95% confidence intervals. *, 
P < 0.001.  
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Figure 4. DAPK3 depleted acini exhibit increased apoptosis. Fluorescent confocal microscopy 
analysis of acini stained for cleaved caspase 3 (CC3, green) and DNA (TOPRO3, blue). Depicted 
here is a representative of three independent experiments. Error bars indicate 95% confidence 
intervals. *, P < 0.0001 relative to control. 
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Figure 5. DAPK3 depleted acini display increased ethidium bromide positive cells. Live 
MCF10A acini stably expressing negative control or shDAPK3 hairpins were incubated with 1 
µg/ mL ethidium bromide at day 6 and subsequently analyzed. Shown here is a representative of 
three independent experiments. Error bars indicate 95% confidence intervals. **, P < 0.0001. 
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Figure 6. DAPK3 depleted acini show proper localization of apical-basolateral markers. Day 6 
structures were analyzed for proper localization of apical marker giantin (red, top panel) and 
basolateral marker integrin α6 (red, bottom panel) along with DNA stain (TOPRO3, blue). Scale 
bars, 100µm. 
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Figure 7. Stable overexpression of DAPK3 inhibits acini growth. (A) Fluorescent microscopy of 
live acini stably overexpressing GFP or GFP-DAPK3 at day 8. Scale bar, 100µm. (B) Size 
analysis of day 8 GFP+ acini from GFP or GFP-DAPK3 stable structures. Error bars indicate 
95% confidence intervals of three combined independent experiments.*, P < 0.0001 relative to 
control.  
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Figure 8. Stable overexpression of a DAPK3 kinase dead point mutant does not alter 
microscopic colony growth. MCF-10A cell stably overexpression empty vector, DAPK3 or 
K42A were grown in soft agar for 3 weeks and then total numbers of microscopic colonies were 
counted. Shown here is a representative of three independent experiments. Error bars indicated 
95% confidence intervals.*, P< 0.001. 
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Figure 9. Increased activation of mTOR specific S6K-S6 pathway upon loss of DAPK3 in stable 
MCF10A cells. Western blot analysis of serum starved MCF10A stable cells grown in 2D and 
treated with media, EGF (10ng/ mL) or insulin (10 ug/mL) for 24hrs. Shown here is a 
representative blot of three independent experiments.  
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Figure 10. Increased phosphorylation of S6 upon loss of DAPK3 in stable MCF10A acini. 
Western blot analysis of MCF10A acini grown on Matrigel for 6 days. Shown here is a 
representative blot of two independent experiments. 
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Figure 11. DAPK3 depleted acini are sensitive to rapamycin and LY294002 treatment. (A) 
Analysis of MCF10A acini grown for 4 days and then treated with 100 nM rapamycin for 4 days. 
Shown here is a representative of two independent experiments. Error bars indicate 95% 
confidence intervals. **, P<0.0001. *, P<0.005. (B) Analysis of MCF10A acini grown for 4 days 
and then treated with varying concentrations of LY294002 (vehicle, 100 nM, 10 µM, or 50 µM) 
for an additional 4 days. Error bars indicate standard deviations of three combined independent 
experiments. *, P<0.03. 
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Figure 12. DAPK3 inhibits acini morphogenesis through mTORC1/ RAPTOR. (A)  Analysis of 
day 4 acini from MCF10A cells stably expressing various hairpins. Shown here is a 
representative of two independent experiments. Error bars indicate 95% confidence intervals. *, 
P<0.01. (B) Depiction of negative regulation of the mTORC1-S6K-S6 pathway by DAPK3. 
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Figure 13. Clinically observed downregulation of DAPK3 mRNA in breast and various cancers 
from the Oncomine database (www.oncomine.org). (A) DAPK3 mRNA is significantly 
decreased in ductal carcinoma in situ (DCIS) relative to normal patient samples. *, P<0.002 (B)   
DAPK3 mRNA is significantly decreased in aggressive breast cancer patient samples compared 
to normal patient samples. *, P<0.04. (C) Significant decrease in DAPK3 mRNA expression in 
pancreatic ductal adenocarcinoma (PDA) relative to normal patient samples. *, P<0.01. (D) 
Significant decrease in DAPK3 mRNA expression in melanoma relative to normal patient skin 
samples. *, P<0.001. 
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CHAPTER 3: DAPK3 IS REQUIRED FOR EARLY MOUSE 
DEVELOPMENT & DISPLAYS DISTINCT EXPRESSION 
PATTERNS IN EMBRYONIC AND ADULT TISSUES 
3.1 Introduction 
  The serine/ threonine death-associated protein kinase (DAPK) family is a relatively novel 
kinase family.  The DAPK family is known to regulate smooth muscle contraction, cell-cell 
adhesion, cytoskeleton dynamics, inflammation, and cardiovascular functions as well as tumor 
suppression through regulation of caspase-dependent and -independent cell death, proliferation 
and autophagy (1).  The DAPK family contains 5 members, including DAPK1 , DRP-1 (DAPK-
related protein 1), DAPK3 (also known as zipper interacting protein kinase (ZIPK),  DRAK-1 
and DRAK-2 (DAPK-related apoptosis-inducing protein kinase-1 and -2), which all share high 
homology within their kinase domain (1). Compared to the prototypical family member DAPK1, 
relatively little is known about DAPK3. DAPK3 contains an N-terminal kinase domain that 
shares 80% amino acid homology with the prototypical DAPK1.  It differs from other family 
members by the presence of a C-terminal leucine zipper motif and the absence of a calmodulin-
regulated (CaM) domain and death domain. Similar to other family members, DAPK3 is 
considered to be a putative tumor suppressor.  Overexpression of DAPK3 in mammalian cells 
results in cell death and cell cycle inhibition while kinase inactivating mutations along with 
recurrent deleterious somatic mutations are observed in lung and breast cancers, respectively (2–
4). Additionally, DAPK3 has been shown to interact with and/ or phosphorylate various proteins 
in vitro including ATF4, AATF, Daxx, Par-4, STAT3, NLK, and AR (2,4–9). 
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  Currently, a fundamental understanding of DAPK3 is limited due to the lack of a 
knockout mouse. Commonly used model systems such as Caenorhabditis elegans, 
Saccharomyces cerevisiae, and Drosophila melanogaster lack clear DAPK3 orthologues, 
thereby hindering traditional genetic interrogation.  Uncovering the physiological contributions 
of DAPK3 is crucial to understanding the clinical and basic research observations described 
above. Furthermore, DAPK1 and DAPK3 inhibitors are currently under development for use in 
smooth muscle related disorders (10,11).  Thus, a DAPK3 deficient animal may indicate 
potentially deleterious phenotypes associated with loss of a functional DAPK3 protein. 
  Given these gaps in the fundamental understanding of DAPK3 we generated a DAPK3 
knockout mouse using a gene trap embryonic stem cell line acquired from the International Gene 
Trap Consortium. Although mechanistically different than traditional flx/ flx knockout strategies, 
gene traps have provided a cost-effective and high throughput means to functionalize the mouse 
genome (12). Described herein is the generation and characterization of the unexpected early 
lethality of DAPK3 null mice. Additionally, we identified a distinct and localized pattern of 
Dapk3 promoter activity within the developing heart and nervous system. We also observed that 
the Dapk3 promoter is active in the myenteric plexus of the large intestine and breast epithelium 
of adult mice. Collectively these results identify a fundamental role for DAPK3 in mouse 
development and identify distinct expression patterns in developing and adult animals. 
3.2 Materials & Methods  
Generation of DAPK3 KO Mice  
The pre-confirmed BayGenomics ES line YTA407, was acquired from the International Gene 
Trap Consortium and injected into albino C57BL/6 mice using traditional techniques. One initial 
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founder chimaera was chosen due to high degree chimerism as assessed by coat color and 
subsequently backcrossed onto a pure albino C57BL/6 background (N6 as determined by speed 
congenics). Polymerase chain reaction genotyping was performed using the following primers: 
Forward 5’ GTGTGCATATGTGTCTTAGTCACAGCAC, Reverse 5’ 
GGCGATTAAGTTGGGTAACGCCAG, Reverse 5’ GACAGTATCGGCCTCAGGAAGATC 
G.  
Southern Blot  
For each southern blot, 5 µg of isolated DNA was digested with SphI overnight at 37°C. 
Digested DNA was run on a 1.0% agarose gel and subsequently transferred to a charged nylon 
membrane after depurination, denaturation and neutralization. After crosslinking, the transfer 
membrane was blocked in pre-heated Hyb Plus Buffer (Sigma) and salmon sperm at 68°C for 2 
hours with constant agitation. Polymerase chain reaction was used to generate the following 
southern probes from heterozygous genomic DNA, Internal: Forward, 5’ 
GACTCGATGGCTGAGGACGGTACGAATG, Reverse, 5’ 
CTCAAGAGGCTGAGGCTGGAGGATTAAACA;  External: Forward, 5’
 CACGGAGAATCCGACGGGTTGTTACTCGC, Reverse, 5’ 
GCACATCTGAACTTCAGCCTCCAGTAC. After gel purification, probes were labeled with 
50 µCi of 32
α
P-dCTP (Perkin Elmer) using the Roche Random Prime Labeling Kit and then 
cleaned on an Ambion Column. Hybridization occurred overnight at 68°C with constant 
agitation. The following day, membranes were washed and subsequently imaged using a 
Phospho-screen and Storm 860.  
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Blastocyst Isolation and Genotyping 
E3.5 embryos were harvested from mated super ovulated females (<6 weeks). Whole genome 
amplification was then performed on individual blastocysts (Sigma WGA4) followed by 
standard PCR genotyping as described above. 
Generation of Embryonic Stem (ES) Cell Lines 
E3.5 embryos were harvested from mated super ovulated females (<6 weeks). Isolated 
blastocysts were then seeded on pre-plated gamma irradiated MEF feeder cells in a 96 well plate. 
Prior to seeding the blastocysts, standard MEF media was changed to the following primary ES 
media: KO DMEM (Gibco), 7.5% KO Serum replacement (Invitrogen), 7.5% ES tested FBS 
(Hyclone), non-essential amino acids (Gibco), L-glutamine (Gibco), 0.1 mM β-mercaptoethanol, 
1,000 Units/ mL leukemia inhibitor factor (LIF), 3 µM CHIR99021, 1 µM PD0325901, 10 µM 
SB431542 and penn/ strep. Plated blastocysts were maintained at 37 C, 5% CO2. Fresh ES media 
was supplemented every 2 days. When a large portion of the inner cell mass had grown out of 
the attached blastocyst the well was trypsinized and plated onto a pre-plated MEF layer in a 96 
well plate similar to before. Once ES colonies were clearly apparent the culture was serially 
passaged up to a T25 at which point multiple freeze downs were made.  
Quantitative PCR (qPCR)  
The TaqMan Assay was used to quantify Dapk3 mRNA isolated (RNAeasy) from genotype 
confirmed ES lines. FAM conjugated probes were manufactured by Life Technologies/ Applied 
Biosystems that were complimentary and spanned exons 8-9 of the endogenous mouse Dapk3 
locus (Mm00492083_g1). A VIC conjugated mouse actin probe was used as a control.  
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Immunoblotting  
Harvested cells were re-suspended and sonicated in radioimmunoprecipitation assay (RIPA) 
buffer (50mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic 
acid) containing protease and phosphatase inhibitors (1mM phenylmethylsulfonyl fluoride 
(PMSF), 0.4 U/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM β–glycerophosphate, 
0.1 mM NaF, 0.1 mM NaVO4). Proteins (30 to 80 g) were fractionated on 10% Tris-HCl, 
Criterion Precast Gel (Bio-Rad). Separated proteins were transferred onto polyvinylidene 
difluoride (PVDF) membranes (Millipore), and probed with the following antibodies: rabbit anti-
DAPK3/ ZIPK (Cell Signaling, 2928), rabbit anti-β catenin (Santa Cruz, H-102), rabbit anti-
Actin (Sigma-Aldrich, A2066) and rabbit IGG fraction against β-galactosidase (MP, 08559761). 
Tissue prep, fixation and β-galactosidase activity 
Embryos were fixed in 0.2 % glutaraldehyde for 20 minutes at 4°C and then washed twice for 10 
minute in wash buffer (0.1M phosphate buffer pH7.3, 2 mM MgCl2, 5 mM EGTA, 0.01% 
sodium deoxycholate and 0.02% NP40). Washed embryos were then stained overnight at 37°C in 
the following staining solution: wash buffer, 5 mM potassium ferrocyanide, 5 mM potassium 
ferricyanide and 1 mg/ mL Xgal. The following day embryos were fixed in 10% 
paraformaldehyde for 30 minutes and then washed 3 times in PBS for 10 minutes each. Whole 
mount photography was performed after embryos were serially incubated in 50%, 75% and 90% 
glycerol. For intestinal fixation and β-gal activity, the same protocol was generally followed as 
described above.  
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Immunofluorescence  
Mammary glands from 8 week old female littermates were dissected and fixed in 4% 
paraformaldehyde for 1 hour at 4°C.  Glands were then washed twice for 5 minutes in PBS at 
4°C.  Subsequently, glands were immersed in 15% sucrose for 4 hours at 4°C and then 30% 
sucrose overnight at 4°C.  The following day glands were embedded in OCT and stored at -80°C 
overnight. 10 µm sections were placed on Superfrost/ Plus charged slides and stored at -80°C 
overnight. For labeling, slides were thawed at room temperature for 10 minutes and then washed 
for 5 minutes in PBS to remove OCT residue. Slides were then blocked with 10% donkey serum, 
1% bovine serum albumin, 0.2% non-fat dry milk and 0.3% Triton X-100 in PBS for 1.5 hours at 
room temperature. Slides were then incubated with respective primary antibodies in blocking 
buffer overnight at 4°C in a humidified chamber. The following primary antibodies were used: 
rabbit anti-β-galactosidase (MP, 559761) and mouse anti-E-cadherin (BDbiosciences, 610182). 
Slides were washed three times for 5 minutes with PBS and then incubated with fluorophore 
conjugated secondary antibodies (Alexa Fluor 488 or 594) diluted in blocking buffer for 1 hour 
at room temperature in the dark. Slides were then washed three times for 5 minutes in PBS and 
then mounted in DAPI-containing Vecta Shield and imaged using a Nikon Eclipse Ti microscope 
at the same exposure settings and subsequently processed using ImageJ software.  
3.3 Results 
Generation of DAPK3 null mice  
  In an attempt to understand the overall in vivo contribution of DAPK3, we created a 
constitutive DAPK3 knockout mouse using a pre-confirmed gene trap ES line from the 
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International Gene Trap Consortium. The gene trap (Gt) is composed of a 5’ splice acceptor site 
followed by a β galactosidase- neomycin fusion (βgeo) and a polyA tail (Figure 1 A). Initially 
we confirmed that the locus and the entire gene trap were intact and incorporated as a single 
insertion through Southern Blot analysis using both external probes and internal probes on a 
single clonal population of YTA407 ES cells (Figure 1 B). These ES cells were then used to 
generate a mouse using traditional blastocyst injection and animal husbandry techniques that 
were successfully genotyped as seen in the representative genotyping polymerase chain reaction 
(PCR) (Figure 1 B, lower panel).  
Characterization of early embryonic lethality of DAPK3 null mice   
  Overall, heterozygous animals appear to develop and grow normally with no overt 
phenotypes under standard laboratory conditions (Figure 1 C). However, we were unable to find 
homozygous gene trap animals on a mixed 129Ola or backcrossed C57BL/6 (N5) background 
(Table I). We were also unable to locate homozygous gene trap embryos at E12.5, 10.5, and 8.5 
despite near Mendelian ratios for wild type and heterozygous embryos, indicating early 
homozygous lethality (Table I).   
We also observed the presence of several sites of fetal resorption on uteri extracted from 
heterozygous crosses versus heterozygous and wild type crosses (Figure 2 A). We were able to 
isolate and genotype homozygous gene trap blastocysts at E3.5 (Figure 2 B) indicating that 
lethality was potentially occurring post-implantation. Furthermore, there was no difference in 
distribution of homozygous embryos across blastocyst, morula and pre-morula (Figure 2 C).  
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In order to confirm that the gene trap was functional, we used both quantitative PCR 
(qPCR) and immunoblotting analysis. qPCR performed on mRNA extracted from established 
and genotype-confirmed primary embryonic stem cells indicated a gene-dose dependent decrease 
in the expression of Dapk3 mRNA. Specifically, a heterozygous ES lines expressed 
approximately 50% Dapk3 mRNA and several homozygous gene trap lines expressed very little 
Dapk3 mRNA relative to a wild type control (Figure 3 A).  
Next to further confirm a functional gene trap, we attempted to visualize differences in 
DAPK3 protein expression from established primary ES lines. After several discussions with 
technical staffs at various commercial antibody manufacturers we were unable to locate 
antibodies that were able to detect endogenous levels of the mouse 53 kDa DAPK3 protein 
(Figure 3 B). A representative inaccurate antibody is provided that recognized a single protein 
shown to repeatedly migrate lower than 50 kDa. Despite these technical setbacks we were able to 
utilize a β-galactosidase specific antibody that displayed a reactive band that migrated at the size 
calculated to match a protein produced from the fusion of the first 2 exons of DAPK3 and the 
remaining β-galactosidase-neomycin cassette produced by the gene trap (Figure 3 B).  
Embryonic and adult expression patterns of the mouse Dapk3 promoter 
Taking advantage of the functional βgal expressed under the endogenous Dapk3 
promoter we characterized the expression patterns of Dapk3 during the development of 
heterozygous mice. We observed distinct and strong βgal activity in the developing heart of E8.5 
and E10.5 embryos (Figure 4A, B). Additionally, E10.5 heterozygous embryos displayed 
localized activity within the developing notochord (Figure 4B). As expected, no β-gal activity 
was observed in developing wildtype littermates (data not shown). We were also able to 
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visualize localized activity in the developing arms, legs and notochord of E13.5 fetuses (Figure 
4 C).  
We next attempted to visualize Dapk3 promoter activity through β-gal activity and 
immunofluorescence techniques in the large intestine and breast of adult heterozygous mice. 
Strong and distinct β-gal activity was observed in the myenteric plexus (gastrointestinal nervous 
system) of the large intestine (Figure 5 A) with no β-gal activity observed in wildtype littermate 
controls (data not shown). Additionally, immunofluorescence using a β-gal specific antibody 
indicated that the Dapk3 promoter is active in epithelial cells of the mouse mammary gland 
(Figure 5 B).   
3.4 Discussion 
Our work has identified that DAPK3 is necessary for early mouse development and that 
the Dapk3 promoter displays distinct organ and cellular promoter expression patterns. Our 
analysis indicates that DAPK3 deficient blastocysts are able to implant but subsequent 
development is problematic. These results were unanticipated given that DAPK1
 
null mice 
develop normally as indicated by their overall health in common laboratory settings (13). This 
dichotomy raises a number of questions regarding signaling redundancies between DAPK and 
DAPK3 and suggests important DAPK-independent developmental functions for DAPK3. 
Clearly, future investigation is required and our work supports the development of conditional 
DAPK3 knockout mice.   
Our work also suggests that mouse DAPK3 exhibits localized expression in the 
developing heart and nervous system. These expression patterns and our developmental 
observations are of potential relevance to human development as human DAPK3 resides on 
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19p13.3, a region shared by 7 other genes that when deleted results in face and heart structure 
abnormalities, along with intellectual disability and development delay(14). 
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3.5 Figures  
 
Figure 1. Generation and characterization of DAPK3 knockout mice. (A) Schematic 
representation of the Dapk3
Gt(YTA407)Byg
 locus. (B) Southern blot of a correct positional and single 
integration with the endogenous dapk3 locus from the YTA407 ES line. A representative PCR 
genotyping from adult mice is also included. (C) Gross body weight of wildtype versus 
heterozygous adult mice.  
A B
C
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Figure 2. (A) The appearance of increased resorbed E10.5 fetuses (red arrows) in uteri extracted 
from heterozygous crosses (top) versus wildtype-heterzoygous crosses (below). (B) Brightfield 
images of genotype confirmed blastocysts isolated from heterozygous crosses. (C) Distribution 
of early stage homozygous gene trap embryos. 
Dapk3+/+ Dapk3Gt/Gt
B
A
C
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Figure 3. (A) qPCR analysis of Dapk3 mRNA extracted from genotype confirmed primary ES 
cells. (B) Western blot analysis of expression of DAPK3-βgeo protein product in wildtype and 
homozygous gene trap primary ES lines. (C) Embryonic developmental stage distribution of 
genotype confirmed homozygous gene trap embryos.   
 
+/+ +/+ -/- -/- -/-
A
B
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Figure 4. (A) Distinct and localized βgal activity in the developing heart of genotype confirmed 
heterozygous E8.5 embryo (red arrows).  Similar specific localization of βgal activity in the 
developing heart and notochord (red arrows) from genotype confirmed heterozygous E10.5 
embryos. (C) Activity also observed in the developing arms, legs and notochord of E13.5 fetuses.  
 
 
 
E13.5
B
C
A
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Figure 5. (A) Distinct β-gal activity in the myentereic plexus of the large intestine from 10 week 
old heterozygous animals. Shown here is an H&E fusion for topographical comparison. (B) The 
dapk3 promoter is active in the epithelia of mouse mammary glands as visualized using 
immunofluorescence.  
 
 
 
A
B
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3.6 Table 
Table I. Ratios of various genotypes in embryos and adult mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype E8.5 E10.5 E12.5 129Ola C57BL/6
+/+ 4 2 4 39 8
+/Gt 4 5 6 68 13
Gt/Gt 0 0 0 0 0
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CHAPTER 4: CONCLUSIONS & FUTURE DIRECTIONS 
4.1 Conclusions 
Collectively, the data described herein has revealed a novel mechanism by which DAPK3 
exerts its potential tumor suppressive functions and additionally identifies an unexpected role in 
mouse development. Specifically, we have identified that DAPK3 negatively regulates mTOR 
signaling which has functional implications for breast tumorigenesis. Furthermore, complete loss 
of DAPK3 leads to early lethality (E 4.5-6.5) in mouse embryos. The Dapk3 promoter is active 
in the developing heart and nervous system as well as the gastrointestinal myenteric nervous 
system and breast epithelium of adult animals. Our studies suggest that loss of DAPK3 
expression in the breast epithelium can facilitate breast cancer development as reduced DAPK3 
expression is observed in DCIS and aggressive breast cancers relative to normal and DCIS, 
respectively. Overall, both the MCF10A 3D morphogenesis phenotypes and mouse 
developmental defect (s) argue against the clinical use of DAPK3 inhibitors that are currently 
under development and support future studies.  
4.2 Future Directions 
Despite these important discoveries there remains much to be known about DAPK3 and 
other members of the DAPK family. Future DAPK3 research should involve a detailed 
biochemical evaluation of mTOR-S6K-S6 inhibition, identification of functionally relevant 
substrates, identification of translationally repressed target mRNAs, and subsequent development 
of more exquisite and appropriate genetically engineered mouse models for breast cancer 
inquiries. A general discussion of these future studies is discussed in detail below. 
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  Based on the data presented above, DAPK3 negatively regulates S6K-S6 signaling in a 
potentially kinase-dependent manner.  First, kinase-dependency should be confirmed.  As 
discussed, initial attempts involved stably overexpressing a kinase dead mutant (K42A).  
However, these failed potentially due to combined instability of the point mutant and an N-
terminal GFP fusion. Subsequent attempts to ameliorate this set back could involve using 
different fluorescence proteins (mCherry, YFP) and different DAPK3 kinase deficient mutants in 
various N- and C-terminal orientations.  Additional studies are also warranted within different 
cancer cell lines to determine the ubiquity of DAPK3 repression of mTOR signaling. This 
includes a breast cancer-focused panel of benign and malignant breast cancer cell lines along 
with different breast cancer subtypes (luminal A/B, triple negative, and Her2) and also additional 
malignant cell lines derived from non-breast tumors.  The differential growth-factor or nutrient 
deprivation response of various cell lines (lacking or overexpressing DAPK3) should also be 
evaluated within the mTOR pathway.  While my studies have determined that DAPK3 regulates 
mTOR-S6K-S6 signaling potentially downstream of ERK/ AKT mediated activation, additional 
studies should confirm 4E-BP1 regulation. This will help to determine if these is a general 
mechanism or if it is specific to S6K-S6 regulation. 
  Beyond general pathway dissection, further biochemical studies are warranted to identify 
the DAPK3 phosphorylation substrate(s) (herein referred to as protein X) and how this 
negatively regulates the mTOR pathway. While our data indicates potential DAPK3 mediated 
inhibition downstream of mTOR, this should be confirmed through evaluation of upstream 
components. Initial cursory investigations should include surveying known inhibitory 
phosphorylation sites within the mTOR pathway that can potentially be directly or indirectly 
induced by DAPK3.  This could include TSC2 activating phosphorylations by AMPK (T1227 
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and S1345) (1) or GSK3β (S1337 and S1341) (2).  Downstream of TSC1/2, RheB GTPase 
activity should be evaluated.  Additionally, TSC1-TSC2 interaction and differential 
phosphorylation of S6K should be evaluated given that several other DAPK family members are 
known regulate S6K/ S6. These approachable studies will be able to determine if commonly 
regulated nodes within the mTOR pathway are impacted by DAPK3 but screens of some sort 
will be required to identify less obvious regulators.  
  To date, the molecular mechanisms of DAPK3 have only been surveyed by protein 
interactions assays that involve the ectopic expression of DAPK3. Additionally, novel 
phosphorylation substrates have been identified through primary interaction assays as well. 
Alternative approaches to detail the DAPK3-mTOR-S6K-S6 pathway using high throughput 
screens with genetically encoded optical readouts might be inherently flawed due to the 
translational-sensitivity of the optical system output.   Specifically, identifying a normalization 
control that does not respond to alterations in translation would be difficult.  
  One potential method to define the molecular mechanism by which DAPK3 regulates the 
mTOR pathway would be to utilize two dimensional (2D) differential in-gel electrophoresis 
(DIGE) proteomic profiling of immobilized metal affinity chromatography (IMAC) enriched 
phosphoproteins.  This type of phosphoproteomic approach was recently used to identify novel 
ERK-MAPK kinase substrates (3) and these services are offered through proteomics scores such 
as Siteman Cancer Center-Proteomics Core headed  by Dr. Reid Townsend located on the 
Washington University Medical Campus.  DIGE allows for differential labeling of several 
protein populations from different sources to be run in the same gel thereby preventing the 
inherent variability in cross comparisons of 2D-PAGE gels.   
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  This technique could be applied to knockdown and overexpression experiments to 
simultaneously identify substrates based on respective converse outputs from each assay. To 
reduce background labeling and enrich low abundant phosphoproteins, whole cell lysates will be 
run over commercially available IMAC columns. Subsequent elutions will be labeled with 
spectrally distinct Cy3, and Cy5 dyes. Knockdown and over expression of DAPK3 should reveal 
converse phosphorylation events on DAPK3.  Individual phosphoprotein populations will be 
fluorescently imaged within the gel and pseudo-colored digital images will be overlaid to 
quantitatively measure changes in phosphoprotein status between experiments. Selected gel 
features will be selected using DeCyder software, robotically excised, digested and subjected to 
liquid chromatography and tandem mass spectroscopy analysis for simultaneous substrate and 
phosphorylation site identification.   Alternative methods include mass spectroscopy-based semi-
quantitative liquid chromatography mass spectrometry. Herein, lysates would be collected from 
similar cellular conditions, subjected to trypsin digestion, enriched for phosphoproteins using 
IMAC, and subjected to HPLC tandem mass spectrometry. Changes in the relative abundance of 
specific m/z spikes when compared between treatments will be used to semi-quantitatively 
indicate potential differential phosphoprotein status as well as substrate identification.  
  For technical ease, phosphoprotein populations should be extracted from 2D MCF10A 
EGF-stimulation assays similar to those discussed in the western blots above. EGF induces 
robust activation of the mTOR system potentially increasing the sensitivity of phosphoproteomic 
approaches.  After primary identification of putative DAPK3 phosphorylation substrates, 
subsequent in vitro phosphorylation assays with DAPK3 and protein substrates should be 
performed along with respective point mutant controls (DAPK3 K42A-kinase dead, DAPK3-
phosphorylation site mutated protein X).  Subsequently, protein X-point mutants should be 
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overexpressed (S/T/Y->Q or S/T/Y->A) during manipulation of DAPK3 expression to confirm 
respective effects on mTOR activation as regulated by DAPK3. After mTOR regulation is 
confirmed, if possible, monoclonal antibodies directed against the phospho-protein X should be 
used to confirm DAPK3-dependent phosphorylation in vitro and in vivo. Following these studies, 
appropriate targets should be functionally confirmed in the 3D MCF10A morphogenesis assay.  
  It will also be important to further understand the translational program repressed by 
DAPK3. Specifically, which mRNA transcripts are translationally repressed by DAPK3. This 
might lead to identification of novel oncogenes and further detail the inhibitory mechanism of 
DAPK3. To identify which transcripts are translationally upregulated by depletion of DAPK3, 
polysome ribosome profiling followed by gene expression analysis will be performed. Increased 
transcripts present within polysome fractions will indicate increased transcript-specific 
translation. Total mRNA will be collected from 2D MCF10A treated as stated previously and 
appropriate polysome fractions will be collected and submitted for gene expression analysis. 
This approach is supported by the already reported role of DAPK3 repression of transcript-
specific translational in response to interferon-gamma (4).  
  It will also be crucial to investigate the functional similarity between human and mouse 
DAPK3 by developing and utilizing more exquisite genetically engineered DAPK3 mouse 
models. As discussed previously, it has been posited that human DAPK3 and murine DAPK3 
(rat and mouse) differ in localization and sub-cellular functional capabilities (5). Interestingly the 
authors did not show immunofluorescence localization or nuclear-cytoplasmic fractionation data 
for mouse DAPK3 so the exact subcellular localization remains unknown. Our data suggests that 
DAPK3 is expressed in the mammary epithelium and clinical evidence suggests its 
downregulation can facilitate breast cancer development and progression. Regardless of the 
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localization of ectopically expressed DAPK3, endogenous DAPK3 might display a completely 
different localization pattern that cannot be evaluated due to lack of appropriate antibodies. 
These arguments should not hinder the development of additional mouse models given the data 
presented within this dissertation.   
  To technically approach these questions within the context of mouse models of breast 
cancer, one would first need to overcome the early lethality of homozygous null DAPK3 mice 
using a conditional genetic system. This could be done using two systems: transplantation or a 
transgenic-conditional system. Both approaches would first require the generation of a floxed 
Dapk3 mouse such that when Cre-recombinase is conditionally expressed subsequent DAPK3 
expression is appropriately ablated. For transplantation mammary glands post-Cre recombination 
will have to be transplanted into wildtype donors. In order to distinguish and monitor the 
transplanted mammary gland development the conditional mouse and breast tissue will also have 
to express a marker (GFP, LacZ) after Cre-recombination. The second approach would involve 
crossing the conditional DAPK3 mouse with that of a transgenic mouse that expresses Cre within 
the breast under the control of a mammary gland specific promoter such as mouse mammary 
tumor virus (MMTV) or whey acidic protein (WAP) promoters. Downsides of each approach 
involve troublesome viable transplantation for the former and lack of organ-specific expression 
for MMTV/ WAP promoters (6). Results from these studies paired with orthotopic xenografts in 
which DAPK3 is depleted will shed light on the extent of DAPK3’s tumor suppressive properties 
in accurate physiological contexts. Additionally, these conditional models can be crossed with 
other organ/ cancer-specific mouse models to evaluate the functional contribution of DAPK3 
alterations to other diseases and cancers. 
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Statement of Significance 
• Deciphering the complex molecular interactions between cancer somatic lesions and host 
microenvironment are crucial to understanding cancer cell proliferation, migration, 
invasion, and immune evasion, and may guide new anti-cancer therapies. 
• Of equal importance as digitized genomics, the next essential challenge is to functionalize 
the cancer genome and to correctly capture these molecular mechanisms in their proper 
biological context within cancer systems.  
• Molecular imaging with genetically-encoded imaging reporters, especially 
bioluminescence, provides a dynamic and noninvasive analysis platform to resolve the 
cooperative genetic elements of cancer systems at various temporal and spatial scales. 
• Bioluminescence reporters expressed in live cells and mouse models of cancer have 
provided powerful tools to monitor cancer-associated genetic circuits, signaling pathways, 
and drug-targeted protein function in vivo. 
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Abstract 
 Bioluminescent imaging (BLI) is a powerful non-invasive tool that has dramatically 
accelerated the in vivo interrogation of cancer systems and longitudinal analysis of mouse 
models of cancer over the past decade. Various luciferase enzymes have been genetically 
engineered into mouse models (GEMMs) of cancer which permit investigation of cellular and 
molecular events associated with oncogenic transcription, post-transcriptional processing, 
protein-protein interactions, transformation and oncogene addiction in live cells and animals. 
Luciferase-coupled GEMMs ultimately serve as a non-invasive, repetitive, longitudinal, and 
physiological means by which cancer systems and therapeutic responses can be investigated 
accurately within the autochthonous context of a living animal.  
 
 
82#
#
 
Introduction 
Transitioning into the Proper Context 
  Genomic lesions within incipient cancer cells in collaboration with alterations in the 
microenvironment contribute to neoplastic progression (1-3). Tumor cells can modulate the 
surrounding microenvironment to promote the progression of cancer through intrinsic oncogenic 
pathways. Furthermore, key genetic lesions have a profound impact on cancer cell migration, 
invasion and regulation of the immune system through tumor-extrinsic manipulation of the 
microenvironment (4, 5). The importance of the host microenvironment in neoplastic 
progression, independent of tumor manipulation, is also underscored by studies demonstrating 
that fibroblasts, among many other stromal and immune cell types, stimulate growth of pre-
neoplastic and neoplastic cells along with promoting drug resistance (6-8). Given these 
observations, understanding the complex interactions between genomic lesions and tumor 
microenvironment in mouse models is crucial to uncovering new anti-cancer therapies. Thus, 
implementation of molecular imaging within basic research and pre-clinical mouse models of 
cancer has become an essential tool for interrogating these hallmarks of cancer and monitoring 
tumor progression within the proper physiologic context. 
  Currently, the most commonly used types of mouse models of cancer can be grouped into 
primary tumor cells, tumor cell lines and their associated tumor engraftments, or genetically-
engineered mouse models (GEMMs) of spontaneous cancer. Xenograft models entail 
subcutaneous or orthotopic transplantation of human cell lines or primary tumors into an 
immunodeficient mouse while mouse allografts similarly employ orthotopic or subcutaneous 
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host implantation. Although traditional cell line xenografts and mouse allografts have yielded 
limited clinical correlations (9-11), the robust ability of human ‘xenopatient’ models (12)  and 
newly adapted “human-in-mouse” (HIM) cancer models for accurately modeling patient disease 
and predicting patient response have been encouraging (11, 12, 13). However, due to the inherent 
nature of xenograft and HIM models, immune compromised mice are required, and thus the 
contribution of the immune system and the autochthonous tumor stroma cannot be fully 
interrogated. Additionally, these tumors are implanted as a population of late-stage tumorigenic 
cells and do not accurately recapitulate all steps of tumorigenesis. In contrast, GEMMs permit 
investigation of the proper tumor microenvironment, model tumor development from the initial 
genetic alteration in situ to subsequent neoplastic progression to metastasis, and enable tissue-
relevant drug pharmacodynamics (13). Constitutive or conditional GEMMs of cancer 
(transgenic, knock-out or knock-in) as well as chimeric or non-germline GEMMs have proven to 
be of significant interest for cancer biology research as well as accurate predictive models of 
human cancers for pre-clinical drug development (14-16).  
Molecular Imaging with Genetically-Encoded Reporters 
  Regardless of the mouse model, molecular imaging techniques (nuclear, fluorescence, 
and bioluminescence) at both macroscopic and microscopic scales make it possible to explore 
the consequences of the interactions between tumor cells and microenvironment during tumor 
progression in vivo,  in real time. This expanding set of molecular probes, detection technologies, 
and imaging strategies, collectively termed molecular imaging, now provides researchers and 
clinicians alike, new opportunities to visualize gene expression, biochemical reactions, signal 
transduction, protein–protein interactions, regulatory pathways, cell trafficking, and drug action 
noninvasively and repetitively in their normal physiological context within living organisms in 
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vivo (17-21). In particular, integration of genetically-encoded imaging reporters into live cells 
and, more importantly, whole animal mouse models of cancer has provided powerful tools to 
monitor cancer-associated molecular, biochemical, and cellular pathways in vivo (22). 
Traditional means of interrogating these oncogenic-associated biological processes and 
characterizing new anti-cancer therapeutics have relied on invasive techniques that are often 
laborious and only provide a static window of analysis. Microscopic fluorescence imaging with 
green fluorescent protein (GFP) provided pioneering studies of biological activities and cellular 
processes at high resolution (23). Concurrently, molecular probes, contrast agents, exploitation 
of fundamental tissue characteristics, and development of multi-spectral fluorescent and 
bioluminescent (luciferase) proteins and highly sensitive instrumentation, have revolutionized 
non-invasive and longitudinal imaging of cancer biology at the whole organism level.  
  These various imaging modalities and strategies acquire macroscopic information in vivo 
through two basic strategies: injected agents or genetically-encoded reporters. Injected agents 
have contributed significantly to pre-clinical cancer research and also have great potential for 
translation, but require significant optimization and characterization depending on the 
experimental model, biological target, background noise, instrumentation, route of 
administration, and, for human use, are impacted by similar regulatory hurdles as therapeutic 
agents (21, 22). An inherent constraint to the development of conventional injectable agents is 
that the details of synthesizing, labeling and validating a new and different ligand for every new 
receptor or protein of interest impose long cycle times on development. However, genetically-
encoded reporters offer more modular tools for preclinical research, which once cloned into 
appropriate vectors and biologically confirmed, can be quickly applied to a broad array of 
applications with minimal modification (22, 24). While genetically-encoded imaging reporters 
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are under development for use in humans, the potential for immunogenicity and transduction 
inefficiencies raise unique challenges (25). However, genetically-encoded imaging reporters 
represent a technically and biologically robust means of monitoring the dynamics of tumor 
biology with relatively high temporal resolution and various levels of spatial resolution when 
coupled with GEMMs. 
  Imaging of biological processes using genetically-encoded reporters relies on the ability 
of the reporter gene to produce a measureable signal that can be detected and quantified by 
extrinsic instrumentation. Reporter expression and thus signal output is controlled by a 
regulatory element such as constitutive or conditional DNA-promoter system, or subsequent 
peptide fusion that regulates posttranslational modulation of the reporter. Most commonly used 
genetically-encoded imaging reporters produce signal through optical imaging strategies, but 
magnetic resonance imaging (MRI) and radiopharmaceutical (PET/SPECT) approaches have 
been explored. Optical imaging of genetically-encoded reporters can provide image contrast 
through, 1) reporter-mediated enzymatic activation of an optically silent substrate (e.g., light-
producing luciferase-based oxidation of D-luciferin in the presence of Mg2+, ATP, and O2) (22, 
26), 2) photo-excitation signal production (e.g., fluorescent proteins) (23), or 3) reporter-
mediated enzymatic release/trapping of optically-tuned leaving groups (e.g., β-glucuronidase-
mediated hydrolysis of glucuronide groups coupled to NIR imaging dyes (27)). Nuclear imaging 
of genetically-encoded reporters can utilize, 1) enzyme-mediated modification of a labeled 
substrate causing intracellular accumulation or proximal cell association (e.g., HSV1-TK-
mediated phosphorylation of radiolabelled nucleosides for PET imaging) (28, 29), or 2) direct 
import of a labeled tracer (e.g., sodium iodide transporters/ radioiodines for PET/SPECT) (22, 
30). An early innovation for MRI was use of a galactopyranose blocking group coupled to a 
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gadolinium-based relaxivity agent that rendered the MRI contrast agent sensitive to expression of 
the reporter gene β-galactosidase (31). 
  Genetically-encoded reporters with optical outputs, specifically fluorescence or 
bioluminescence, are most commonly used for cancer research in mouse models due to overall 
modest cost, sensitivity and lack of technical restrictions and required regulatory barriers often 
encountered with other approaches. Whole animal fluorescence imaging in vivo suffers from low 
signal-to-noise as a result of background auto-fluorescence, modeling-dependent photon 
quantification, photo-bleaching, low tissue penetration and low resolution (26). In addition, 
fluorescent proteins are known to generate reactive oxygen species (ROS) that can induce 
significant cellular stress under selected conditions (23). However, computed image analysis 
along with laser-induced fluorescence has increased the sensitivity of non-invasive fluorescence 
imaging in vivo (32). Also, compared to other genetically-encoded reporters, fluorescent proteins 
are independent of substrate delivery and pharmacokinetics, are amenable to high resolution 
microscopic analysis, and several new far red-shifted fluorescent proteins have been developed 
that enhance the penetration of photons in vivo (21). 
Bioluminescence imaging has emerged as an invaluable optical imaging tool and has 
become widely adapted to molecular imaging of cancer models in vivo. The major advantages of 
luciferase reporter systems in vivo include essentially zero background signal, high signal-to-
noise imaging, relative ease of signal acquisition, modest cost, user-friendly instrumentation and 
direct measure of live cell mass (ATP-dependent activity). Moreover, luciferase enzymes have a 
shorter half-life (~3-5 hrs for native North American P. Pyralis firefly luciferase and Renilla 
luciferase versus 12-26 hrs for native GFP variants) and are rapidly folded and functional post-
translationally, thereby providing a more robust readout of kinetic processes such as 
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transcriptional activation, protein degradation, reversible protein-protein interactions and other 
rapid biological processes (22, 33, 34). Also, red-emitting firefly and click beetle luciferases with 
relatively higher photon outputs have advanced luciferase imaging beyond the original long 
wavelength luciferase variants, providing further advantages over Renilla/ Gaussia luciferases 
and related mutants that emit at blue or blue-green wavelengths, which, while perhaps useful, 
remain suboptimal for imaging in vivo. However, luciferase enzymes in general are dependent on 
substrate pharmacokinetics, and furthermore, the Renilla/ Gaussia substrate (coelenterazine) is 
transported by P-glycoprotein and auto-luminesces due to auto-oxidation from serum albumin 
(35, 36), which can confound analysis in vivo. Additionally, due to overall low photon output, 
luciferase reporters traditionally have been limited to macroscopic imaging analysis. However, 
recent advances in low-light microscopy technologies have permitted the interrogation of live 
cells and live bioluminescent tissues ex vivo at high magnifications (37-39), a notable advance 
that extends the capacity of BLI. 
   Similar to studies in cultured cells, genetically-encoded bioluminescent reporters in mice 
offer the ability to non-invasively monitor transcriptional regulation, post-transcriptional and 
post-translational events, as well as transformation and neoplastic progression. When coupled 
with an oncogenic protein or signaling pathway of interest, these properties of BLI allow various 
features of cancer to be interrogated such as chemoresistance, inflammation, angiogenesis, DNA 
maintenance, apoptosis, therapeutic response and oncogene addiction. Additionally, BLI reporter 
mice can simultaneously and directly assess tumor burden through constitutive or conditional 
expression of luciferase. With the sensitivity of BLI reporter mice, one can also non-invasively 
survey and monitor small, non-palpable tumors as well as metastases in a relatively fast and 
efficient manner. While a considerable amount of early effort was directed toward fluorescent 
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GEMMs of cancer, only more recently have mouse models been advanced with the versatility of 
BLI. Thus, the development and utility of BLI in GEMMs of cancer is the focus of this review 
and the reader is referred elsewhere for overviews of molecular imaging in non-GEMM models 
(19-22, 40). More specifically, this review highlights GEMMs of cancer reported in the last half-
decade that utilize genomically-encoded bioluminescence reporters for investigating tumor 
biology and associated signaling pathways inherent to the cancer system or pathway of interest, 
summarizes notable models, and suggests future directions for BLI-coupled GEMMs of cancer. 
In addition to the models highlighted in detail below, an extensive referenced list of cancer-
related luciferase-coupled GEMMs according to mode of luciferase regulation (Table I) and 
cancer type (Table II) are included for the general reader.  
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Regulation of Luciferase in GEMMs of Cancer 
Transcriptional 
  Transcriptionally-regulated luciferase enzymes provide a robust tool to monitor tissue-
specific tumor burden or interrogate biological processes in tumors in vivo. Transcriptional 
systems are simple in design and consist of a composite or endogenous promoter sequence 
upstream of luciferase and introduced into the mouse genome either through transgenic or 
targeted knock-in approaches. Conventionally, genetic regulatory elements derived from 
cytomegalovirus (CMV) or simian vacuolating virus 40 (SV40) provide robust protein or 
reporter expression in the cell or tissue harboring the construct. However, at the whole animal 
level, to track spontaneous tumor progression, researchers have utilized promoters or cis acting 
regulatory regions from endogenous or viral genes activated specifically in neoplastic cells. For 
example, prostate growth and development is largely governed by androgen signaling, thus 
offering an avenue to specifically image prostate cells in physiological or pathological states. 
With this in mind, a plethora of transgenic luciferase mice have been developed utilizing 
composite promoters from human kallikrein 2, probasin, prostate-specific antigen and various 
forms of concatenated minimal androgen response elements (Table I). Other transgenic models 
also use endogenous androgen-responsive promoters derived from rat probasin and human 
prostate specific antigen (41, 42). Baseline signal with varying intensities is confined to the 
prostate with minimal promoter activity outside of the prostate for most models, allowing non-
invasive prostate-specific BLI. Prostate bioluminescent signal from these promoters correlates 
with normal prostate development and decreases upon castration or androgen ablation. However, 
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in only one transgenic model (Tg(PSA->Luc)) did the reporter mouse demonstrate an increase in 
prostate bioluminescence when crossed to a previously characterized TRAMP model that 
expresses oncogenic SV40 small and large T antigen in the prostate via a minimal rat probasin 
promoter (42). Two other similar prostate transcriptional luciferase reporter models failed to 
show a consistent increase in prostate signal when crossed to TRAMP models despite 
histologically confirmed tumor progression (43, 44). It was suggested that the inability of these 
reporter models to show a tumorigenic increase in prostate bioluminescence, as seen in Tg(PSA-
>Luc; rPB-Tag) mice, was due to the androgen independence of these aggressive, 
neuroendocrine carcinomas that are characteristically observed on a FVB background (45). 
However, this observation is unsatisfying given the fact that if the tumors were truly AR-
independent, the relatively high prostate-specific signal (>106 photons) would be, by default, 
representative of tumor mass only and would have been expected to increase along with the 
tumor, which was not observed despite tumor progression (43, 44). These discrepancies point out 
the potential pitfalls of using transgenic strategies with regulated promoter-based reporters for 
readout of tumor burden which can be confounded by gene locus effects, gene silencing, or 
tumor evolution, independent of promoter- or gene-dependent luciferase expression. This 
discordance can be investigated by correlating bioluminescence with tumor burden as measured 
by an alternative means (caliper measurements, MRI, etc.). Conversely, bioluminescent promoter 
systems in transgenic GEMMs of cancer that are intended to interrogate gene-associated 
oncogenic processes can ultimately become a measure of tumor burden alone, completely 
separate from the original gene-associated biological intent. Thus, care should be taken when 
developing a reporter mouse using luciferase (or any reporter gene) to monitor tumor hallmarks 
when coupled to a gene of interest.  Transcriptional bioluminescent reporters knocked into an 
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endogenous locus or immediately downstream of a start codon also provide a means to monitor 
tumor biology and development in vivo with decreased signal variability compared to that often 
observed between transgenic founder lines. Although technically more difficult, knock-in 
strategies maintain the entire promoter regulatory region adjacent to the luciferase gene and thus, 
in principle, provide a more accurate measure of gene transcription within the native context of 
the genome. This is exemplified in a p21Waf1/CIP knock-in luciferase model (p21FLuc) in which 
firefly luciferase was genetically introduced into the endogenous p21 locus downstream of the 
native promoter (Fig. 1A) (37). p21 is a critical regulator of cell cycle progression, is a direct 
transcriptional target of p53 among many other signaling pathways and is frequently altered in 
human cancers (46). As expected, p53-dependent activation of the p21 promoter in response to 
external beam irradiation (IR) could be non-invasively and repetitively monitored over time in 
p21FLuc mice (37) using surgically implanted micro-osmotic pumps that constantly delivered D-
luciferin substrate (47) (Fig1. B). Previous attempts to non-invasively monitor p21 levels in vivo 
utilized transgenic transcriptional luciferase or lacZ reporter mice that were regulated by short 
fragments of the p21 promoter (<5 kb) and only produced robust signal when strains harbored 
multiple copies of the reporter (up to 23) (48, 49). In the knock-in reporter strain, baseline 
bioluminescence levels three logs higher than the luciferase transgenic strain allowed Tinkum et 
al. (37) to identify specific organs that contained high levels of p21 independent of p53 status. 
Additionally, select organs showed dramatic regional differences in p21-luciferase activity that 
was identified using high-resolution bioluminescence microscopy to localize live sub-organ 
structures and specific cell populations with high-level expression of p21 (Fig. 1C), providing 
new insight into future lines of investigation. 
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  Similar to organ-specific imaging in the aforementioned prostate transgenic models, sub-
cellular whole animal imaging of tumor burden can be accomplished using transcriptional 
reporter mice as well. Scotto et al. (50) introduced a mCherry-Luciferase fusion into the 
endogenous CD19 locus. This enabled non-invasive longitudinal imaging and microscopic 
analysis ex vivo of the B-cell lineage under normal and pathologic conditions when crossed to a 
λ-MYC transgenic mouse model of spontaneous B-cell lymphoma (50). Knock-in strategies 
appear to offer more refined imaging of whole organs or distinct cell lineages in terms of 
sensitivity and specificity when it comes to analysis of GEMMs of cancer at the macroscopic 
scale.  
  However, a caveat is that knock-in strategies can potentially disrupt expression of the 
endogenous locus by usurping its promoter function or preventing expression of the targeted 
locus, thereby disrupting the process under investigation. In this regard, several groups have 
adapted viral internal ribosome entry sites (IRES) to couple translation of luciferase enzymes to 
the transcriptional activation of an upstream gene in a bicistronic fashion while maintaining 
expression of the targeted gene. One group utilized this strategy by knocking-in an IRES-EGFP-
luciferase fusion downstream of the endogenous vascular endothelial growth factor receptor 3 
stop codon (Vegfr3EGFPluc) (Fig. 2A) (51). VEGFR3 is a potent regulator of angiogenesis, 
lymphangiogenesis and metastasis and is emerging as an alternative target in combination with 
other VEGF anticancer therapeutics (52-54). The authors used this reporter mouse to quantify the 
association between inflammation and lymphangiogenesis during wound healing and in response 
to a contact hypersensitivity inflammation model. Microscopic analysis of the coupled EGFP 
reporter allowed the authors to show that Vegfr3EGFPluc luciferase intensity correlated with 
increased lymphatic network density. Additionally, tumor-activated lymphangiogenesis was 
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observed in DMBA/TPA-skin papillomas and at lymph nodes distant from subcutaneous 
injection of B16-V5 melanoma cells (Fig. 2B-C). Importantly, the sensitivity and longitudinal 
capability of luciferase imaging permitted identification of tumor-activated lymphangiogenesis at 
distant lymph nodes that preceded tumor metastasis (Fig. 2C).  
Post-Transcriptional 
  The luciferase enzyme can also be coupled to post-transcriptional mechanisms that 
monitor mRNA modifications associated with oncogenic signaling. This can be accomplished by 
coupling or fusing a luciferase enzyme to a coding sequence such that modification or interaction 
of the mRNA or protein results in modulation of luciferase signal. This strategy was applied to 
investigate the effect of the tumor microenvironment on tumor unfolded protein response (UPR) 
and endoplasmic reticulum (ER) stress in live animals by visualizing alternative splicing (55). 
The heterogeneous tumor microenvironment imposes ER stress upon the tumor through hypoxia, 
acidic pH and low nutrients (56). These constraints, along with deregulated translation and 
proteotoxicity place evolutionary pressure on developing cancer cells, which can respond by 
augmenting several key steps of the UPR pathway for survival. Thus, UPR is an emerging target 
for anti-cancer therapies (56). Upon loss of ER homeostasis, activation of inositol-requiring 1α 
(IRE1α), one of the three UPR pathways, results in unconventional splicing of a 26 bp intron 
from IRE1α-X-box binding protein 1 (XBP-1), thereby incorporating an extended open reading 
frame that increases protein stability and augments XBP-1 transcriptional activation of essential 
UPR response genes (57, 58). Spiotto et al. (55) created a transgenic mouse that harbors a CMV-
>XBP1-Luc transgene which is regulated in a manner similar to that of the endogenous XBP1 
and thus, luciferase expression is a direct readout of this splicing event (55). Under normal 
physiological conditions, the reporter mouse maintained background photonic levels, but 
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appropriately displayed tumor-specific signal once crossed to breast cancer models such as, 
Tg(MMTV-TAg) and Tg(MMTV-Her2), that localized with ER stress markers upon microscopic 
analysis of tumors. Importantly, the authors observed no correlation between tumor size and 
bioluminescent signal suggesting XBP1-Luc was a measure of the tumor-intrinsic ER stress and 
not overall tumor load. Tumors arising within the same mouse possessed variable signal 
intensities, which portrayed the heterogeneic nature of tumor metabolism as further indicated by 
differential glucose uptake and hypoxia, and the contribution of the unique tumor 
microenvironments within the same mouse. These observations serve as an example of the 
sensitivity of BLI compared to other optical imaging modalities that were employed in a similar 
transgenic Tg(XBP1-GFP) mouse, which had very low signal that at the time only allowed 
endpoint analysis of XBP1 activation in a few extracted organs (59).  
Post-Translational 
Cancer-associated post-translational modifications and the subsequent effects on protein 
processing and protein-protein interactions are amenable to luciferase reporter mice and BLI in 
general. Previous designs and biologically affirmed reporters have transitioned from cell culture 
to provide the framework for whole animal preclinical evaluation of anti-cancer drugs in the 
proper physiological context. Interrogation of inhibitors of the hypoxia inducible transcription 
factor 1α (HIF-1α) have been aided by the development and application of various transgenic 
mouse models that fused the oxygen-dependent degradation domain of HIF-1α to firefly 
luciferase (Tg(ODD-Luc) and Tg(Hypoxic RE->ODD-Luc)) (60-62). Under normoxic 
conditions, endogenous HIF-1α protein is retained at low levels due to hydroxylation, 
polyubiquitination and subsequent proteasomal degradation and correspondingly, luciferase 
background signal levels are low in these luciferase reporter mice during normoxia (63). During 
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hypoxia or hydroxylase inhibition, HIF-1α is stabilized and appropriately, bioluminescence 
intensity of these reporter mice increases as a result, thereby indirectly monitoring HIF-1α-
dependent responses to acute or chronic hypoxia. When crossed to spontaneous Tg(MMTV-
neu);Beclin1+/fl or carcinogen susceptible RasH2 cancer models, increased bioluminescence was 
detected in hypoxic tumors, highlighting the ability to monitor both tumor growth and tumor 
hypoxia non-invasively with this reporter mouse (60, 62). Additionally, inclusion of cis acting 
hypoxia response elements before a minimal CMV promoter in the Tg(HRE->ODD-Luc) mice 
inherently provided interrogation of the transcriptional phase of the HIF-1α positive feedback 
loop, which attempts to recapitulate HIF-1α-dependent transcriptional activation of its own 
mRNA (62).  
The analysis of druggable oncogenic protein-protein interactions can also be interrogated 
non-invasively using luciferase reporter mice. This notion is exemplified in a proof-of-principle 
mouse model utilizing the Gal4-VP16 “two hybrid”  interaction system in which nuclear 
interaction of the DNA binding domain of the yeast transcription factor Gal4 with the 
transactivation domain from herpes simplex virus VP16 protein can functionally lead to the 
transcriptional activation of a Gal4 responsive reporter gene (64). If each component is 
individually fused to a set of proteins known to interact, visualization of their proximity and 
interaction can be indirectly assessed through Gal4-responsive reporter activation. Pichler et al. 
(64) generated a transgenic mouse harboring a luciferase reporter regulated by Gal4 response 
elements which could indirectly monitor protein-protein interactions by hydrodynamic somatic 
gene transfer of constructs expressing Gal4 fused to p53 and VP16 fused to the SV40 large T 
antigen. Using this reporter mouse, abrogation of p53-TAg interaction due to loss of p53 was 
readily observed in mice upon shRNA-mediated knockdown of p53 in vivo. Adapting this 
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modular system to other models of protein interactions could aid in the preclinical evaluation of 
modulators of oncogenic protein-protein interactions longitudinally in whole animals (65).  
Conditional Transformation 
  Exquisite genetic techniques have enabled researchers to initiate and follow 
transformation, progression, invasion, metastasis, therapeutic response and oncogene dependence 
in spontaneous or conditional GEMMs of cancer. Luciferase reporter mice can be genetically 
coupled to these molecular and biological events, thus permitting longitudinal and non-invasive 
imaging of a relatively small cohort of mice that can provide statistically meaningful results 
since each animal serves as its own control. In one example, inactivation of the retinoblastoma 
(RB) tumor suppressor pathway in response to platelet-derived growth factor (PDGF)-induced 
oligodendrogliomas was indirectly monitored through activation of a E2F1 promoter driving 
luciferase in an engineered transgenic reporter mouse (66, 67). Direct monitoring of genetic 
deletion of tumor suppressors or activation of oncogenes is also possible through the use of 
several floxed firefly luciferase transgenic mice in which Cre-mediated excision of an upstream 
floxed-stop cassette allows downstream luciferase expression. Previously, Lyons et al. generated 
a transgenic strain in which the beta actin promoter-driven luciferase expression is regulated by 
removal of a floxed GFP-polyA transgene (68). Crossing the reporter strain with a floxed 
Kras2v12 followed by adeno-Cre inhalation induced lung adenocarcinomas that could be 
simultaneously monitored using BLI for over 100 days. Using the same reporter mouse crossed 
to a conditional prostate-specific Cre-expressing strain, Tg(PB-Cre4);Ptenfl/fl, another group was 
able to monitor for over 400 days spontaneous prostate adenocarcinoma initiation, progression, 
response to castration and subsequent development of castration-resistant prostate cancers 
(CRPC) reliably in a small cohort of animals (69). The emergence of CRPC was not observed 
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and potentially may never be observed through coupled-reporter gene imaging in the androgen-
dependent transcriptional prostate carcinoma reporter models discussed earlier. This highlights 
the utility of Cre/loxP approaches, which can mark tumor cell lineage prior to biologic-specific 
functions, thereby improving upon the complexities of transcriptional reporters, such as the 
prostate cancer reporter mice discussed above. The authors observed that the non-recombined β-
actin promoter-driven reporter was leaky and read-through could be observed in muscle tissue 
using reverse transcriptase PCR of tissue mRNA. This was potentially due to the strength of this 
promoter in regions of high actin expression and/or from the variability associated with the loci 
or extent of genomic integration of the reporter. Also, the authors observed pronounced 
luciferase signal at intraperitoneal sites of repeated luciferin injection, which could be remedied 
through tail vein injection of the luciferase substrate. Svensson et al. also utilized a conditional 
Rosa-Luc knock-in reporter mouse to monitor prostate carcinoma progression on the less 
aggressive C57BL/6 background (70), using the same strategy as Liao et al. (Tg(PB-
Cre4);Ptenfl/fl) (71). Despite the now well-characterized differences in prostate development due 
to the genetic backgrounds of the mouse used (e.g., C57BL/6 versus aggressive FVB/N), 
Svensson et al. noted a dramatic reduction in luciferase signal variability over time compared to 
Liao et al. These differences potentially stem from the Rosa26 locus and/ or the fact that the 
Rosa-Luc mouse was strategically backcrossed onto an albino C57BL/6 background, thereby 
greatly reducing signal attenuation due to coat color. Additionally, analysis of Tg(PB-
Cre4);Ptenfl/fl prostate tumors indicated the BLI was a more accurate readout of prostate tumor 
burden because ex vivo analysis revealed massive fluid retention in the anterior prostate that 
could be misinterpreted as tumor mass when analyzed via MRI.  
 
 
98#
#
  Cre/LoxP-luciferase reporter mice have also been used for following stochastic neoplastic 
genetic lesions and marking distinct cell lineages when coupled to other fluorescent or LacZ 
reporter strains. Liu et al. implemented this strategy to identify organ susceptibility and monitor 
subsequent tumor progression in a sophisticated whole animal Notch1 loss-of-heterozygosity 
(LOH) model crossed to a floxed stop cassette-Rosa26-click beetle red luciferase (Rosa->CBR) 
knock-in reporter mouse (Fig. 3) (72). The authors generated a mouse harboring a knock-in non-
functioning Notch1-Cre fusion on one allele along with a conditional Notch1 knockout cassette 
on the second allele (Notch1fl), which was further crossed with either the conditional Rosa->CBR 
mouse or other conditional Rosa->LacZ and Rosa->EYFP reporter mice strains (Fig. 3A). 
Following the first round of embryogenic Notch1 expression, any second endogenous ligand-
dependent activation of Notch signaling in Notch1-Cre;Notch1fl mice results in cleavage and 
subsequent nuclear translocation of the Notch-intracellular-domain (NCID)-Cre fusion, which in 
turn results in excision of the remaining floxed Notch1 allele throughout all active Notch1-
signaling cells (Fig. 3A). Thus, stochastic LOH and the subsequent development of highly 
vascularized tumors could be indirectly monitored at the macroscopic (Rosa->CBR) and at the 
cell lineage level (Rosa->LacZ/EYFP) by Cre-mediated excision of the co-engineered lox-stop-
lox cassette inserted upstream of the Rosa locus on each allele in these reporter mice (Fig. 3B, 
C). The Rosa->CBR mouse has since been crossed with the Rosa->LacZ mouse to create a 
conditional Rosa->CBR/ LacZ dual-modality reporter mouse that has been extensively 
backcrossed onto the albino C57BL/6 background (Piwnica-Worms, D. et al. unpublished). This 
dual reporter mouse has the potential to provide a robust and powerful readout of Cre-activation 
and carcinogenesis through the high, red-emitting photonic output of CBR and the microscopic 
utility of LacZ staining.  
 
 
99#
#
Tet-Regulated Systems 
  Conditional cancer mouse models using genetically-coupled luciferase reporters can also 
utilize tetracycline (or the more stable analogue, doxycycline)-regulated expression systems or 
tamoxifen-inducible systems for spatial and temporal induction and reversion of oncogene 
biology in mice. However, tetracylcine (tet)-systems are more commonly used due to toxicities 
associated with tamoxifen and the Cre-estrogen receptor fusion observed in tamoxifen-inducible 
mice (73, 74). In the tet-on system, expression is dependent on binding of a reverse tetracycline-
regulated transactivator (rtTA) to the tetracycline-response promoter elements in the tet-operator 
(tet-o) engineered upstream of the coding sequence of interest in the presence of tetracycline 
(75). The tet-off system uses a different tetracycline-regulated transactivator protein (tTA) which 
cannot bind tet-o in the presence of tetracycline, effectively silencing expression only when 
tetracycline is present (75-77). Regardless of the system, expression of the tetracycline 
transactivator (and hence the gene of interest) can be regulated through promoters specific to a 
tissue or cell type of interest. Ultimately, these systems have been instrumental in determining 
the extent of oncogene dependence in spontaneous mouse tumor models within the proper 
context in vivo. Additionally, conditional repression of an oncogene mimics therapeutic 
inhibition in a targeted molecular pathway and coupled luciferase reporters allow longitudinal 
imaging confirmation of this ‘therapeutic inhibition’. In one example, Du et al. generated a 
conditional tet-o-polyoma middle T antigen (PyMT)-IRES-luciferase reporter mouse, Tg(tet-o-
PyMT-IRES-Luc), to investigate the cell-specific effect of oncogene induction on the 
development and progression of pancreatic cancer using two previously reported conditional Tet-
system mice Tg(Rip7-rtTA and Pdx1-tTA) (78). Within 1 day of doxycycline removal, non-
invasive BLI imaging allowed confirmation of subsequent oncogene withdrawal in Tg(Rip7-
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rtTA; tet-o-PyMT-IRES-Luc) mice. Interestingly, this had no effect on the established 
hyperplastic β cell islets, indicating oncogene independence, which was also conversely 
confirmed using the Pdx1-tTA mice. Additionally, 10% of Tg(Pdx1-tTA; tet-o-PyMT-IRES-Luc) 
mice developed aggressive acinar cell carcinomas as a result of activation of the Pdx1 promoter 
in early pancreatic progenitor cells. Regression of these tumors when deprived of PyMT, 
confirmed as soon as 1 day after doxycycline addition by BLI, indicated a requirement or 
dependence on PyMT for sustained tumor maintenance. Another group generated a tet-off 
luciferase reporter mouse to delineate the requirement of MYCN in medulloblastoma (79). One 
of the two lines crossed to generate this bigenic mouse contained the cerebellum-specific 
glutamate transporter1 (Glt1) promoter driving expression of tTA and the other a tet-o-driven 
bidirectional MYCN and firefly luciferase expression cassette. Using a characterized amount of 
photon flux as a measure of tumor burden, the authors repressed MYCN expression in a subset 
of mice by feeding them doxycycline-containing chow. Within one week, they observed a 
dramatic drop in bioluminescence and tumor regression, confirming the requirement for 
sustained MYCN expression in these tumors and suggesting its potential for targeted therapy in 
medulloblastomas. Thus, bioluminescent reporter mice coupled to integrated conditional tet-
regulated systems are invaluable tools to quickly and efficiently monitor oncogene expression in 
manageable cohorts of mice and validate potential therapeutic targets, which guide and inform 
more invasive and laborious secondary tumor analyses.  
Lessons Learned and Future Considerations 
  As with all experiments, meticulous planning and a dose of foresight are paramount to 
the success of engineering a genetically-encoded luciferase mouse. There are several 
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considerations and nuances that can dramatically reduce time and labor and expand upon the 
potential of a reporter mouse in terms of signal sensitivity, biological accuracy and overall 
utility. As the genetic background of the mouse strain can dramatically affect the biology of the 
cancer, for example, as seen in the differential sensitivity of C57BL/6 and FVB strains to 
prostate cancer models as well as other models (80), so will genetic background inherently 
modulate the signal strength and interpretation of coupled luciferase reporters. When possible, an 
albino mouse strain should be used to minimize signal attenuation. This will allow for enhanced 
sensitivity for gross analysis of luciferase expression, and will strongly benefit low luciferase-
expressing tissues in scenarios such as low endogenous expression, metastasis or tumor 
regression. Commercial albino C57BL/6 embryonic stem cells are now available that have high 
germline rates, and are technically amenable to genomic manipulation for targeted or transgenic 
reporter approaches, thereby minimizing onerous backcrossing. When specifically attempting to 
monitor live tumor cells, a relevant genetically-encoded reporter should be specific to live cell 
mass alone and will likely be most accurate when using Cre/loxP-based or knock-in strategies as 
discussed previously. Although technically much simpler, transgenic transcriptional reporters 
can be overridden by tumor evolution or genomic loci effects as seen in the androgen-sensitivity 
GEMMs of prostate cancer discussed above. Low light microscopy, which is capable of imaging 
live luminescent tissues, is becoming accessible to the general researcher and is approaching the 
high levels of magnification and resolution necessary for subcellular inspection. Nonetheless, 
analysis ex vivo of live tissues and organs synergizes with the whole animal imaging capabilities 
of luciferase reporter mice and also can be performed using luciferase antibodies or secondary 
coupled reporters such as fluorescent proteins as used to observe lymphatic vessels in 
Vegfr3EGFPluc  mice (51).  
 
 
102#
#
 
Conclusions 
  Genetically-encoded luciferase reporter mice have made a profound impact on imaging 
tumorigenesis, cancer progression, response to therapies and the contributions of the tumor 
microenvironment when crossed with GEMMs of cancer. Compared to other imaging modalities, 
bioluminescence provides an efficient, relatively low cost, non-invasive and longitudinal means 
to investigate genetic alterations in the autochthonous tumor environment and its ultimate effect 
on tumor biology. Combining the advantages of genetically-encoded luciferase reporters with the 
development of new and clinically accurate GEMMs of cancer paints a bright horizon for our 
understanding of molecular cancer biology and the development of novel and durable anti-cancer 
therapies. 
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A.3 Figures 
A
C
B
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Figure 1. Whole animal imaging of p21 promoter activity. (A) Schematic representation of 
p21FLuc reporter mice with luciferase knocked into the endogenous p21 locus. (B) Non-invasive, 
whole animal imaging of p53-dependent p21 promoter activity in response to radiation in 
p21+/FLucTrp53+/+ and p21+/FLucTrp53fl/fl mice. (C) Low-light, bioluminescence microscopy of 
p21 promoter activity in various p21+/FLuc live tissues, including the villi from the small intestine, 
throughout the liver, in the epithelial cell layer below the keratinized penile spines, as well as the 
epithelial cell layer of the vagina. Bars, 200 µm; 50 µm for the penis. Images were modified and 
reprinted with permission from Molecular and Cellular Biology. 
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Figure 2. Imaging inflammation and tumor-associated lymphangiogenesis. (A) Schematic 
representation of the Vegfr3EGFPluc reporter knocked in downstream of the endogenous Vegfr3 
locus, which utilizes an internal ribosome entry site (IRES) for monitoring Vegfr3 expression. 
(B) DMBA/TPA-induced skin papillomas in Vegfr3EGFPluc/+ reporter mice displayed localized 
lymphangiogenesis as indicated by the black arrows. (C) Whole body imaging of tumor-
activated lymphangiogenesis over time in a B16-V5 melanoma xenograft model at distant lymph 
nodes (red arrows) prior to metastasis of the primary tumor xenograft in female Vegfr3EGFPluc/+ 
reporter mice. Images modified and reprinted with permission from Proceedings of the National 
Academy of Sciences.  
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Figure 3. Imaging whole animal Notch1 loss-of-heterozygosity (LOH) and surveying subsequent 
tumor development. (A) Schematic representation of Notch1-Cre;Notchfl; Rosa->CBR cells prior 
to Notch1 ligand activation. (B) Upon activation, cleavage of NOTCH1 (between S2 and S3) 
permits translocation of the Notch-intracellular-domain (NCID)-Cre fusion into the nucleus 
where it excises both the remaining wildtype Notch1fl allele, and the floxed stop cassette 
preceding CBR. Through these series of Cre-mediated excisions, lineage tracking of Notch1 
LOH can be longitudinally imaged via the genetically-coupled floxed Rosa->CBR reporter. (C) 
Whole animal imaging of the development and progression of Notch1 LOH-induced 
angiosarcomas of the liver as imaged in Notch1+  or  Notch1fl mice crossed to Notch1-Cre;Rosa-
>CBR reporter mice. Images modified and reprinted with permission from Journal of Clinical 
Investigation.  
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Table I. Cancer-Associated Processes Observable in Genetically-Encoded Luciferase Reporter Mice. 
Mode of Regulation Cancer Biology Target Genetic Strategy Ref. 
    
Transcriptional 
   
  
Cell cycle KI(p21 promoter->Luc) (37) 
  
B-cell specific imaging KI(CD19 promoter->Luc) (50) 
  
Various KI(Cox-2 promoter->Luc) (81) 
  
Various Tg(Egr1 promoter-> Luc) (82) 
  
Chemoresistance KI(Mdr1a promoter->Luc) (83) 
  
Lymphangiogenesis KI(IRES-EGFP-Luc  downstream of Vegfr3) (51) 
  
Apoptosis Tg(Birc5 promoter-> Luc) (84) 
  
Telomerase regulation Tg(hTERT BAC->Rluc) (85) 
  
Angiogenesis Tg(Vegf promoter->TSTA-Luc) (86)  
  
Angiogenesis Tg(Vegfa promoter->EGFP-Luc) (87) 
  
Angiogenesis Tg(Vegfr2 promoter->Luc) (88) 
  
Various Tg(NF-κB RE-> Luc) (89) 
  
Various Tg(Smad 2/3 RE-> Luc) (90) 
  
Cre mediated Rb inactivation in pituatary gland. Tg(Pomc promoter-> Luc) (91) 
  
PDGF induced inactivation of Rb pathway Tg(E2f1 promoter->Luc) (67) 
  
PDGF-induced activation of Gli1/2 Tg(Gli1/2 responsive promoter->Luc) (92) 
  
Prostate specific imaging Tg(Pbsn promoter + androgen response elements->Luc) (41) 
  
Systemic response to anti-androgen therapy Tg(Slp-androgen response elements -TK->Luc) (93) 
  
Afp activation in DEN induced HCC KI(Afp promoter->TK-IRES-Luc) (94) 
  
Afp activation in DEN induced HCC Tg(Afp promoter -> Luc) (95) 
  
Androgen deprivation in normal prostate, TAg, and JOCK models Tg(syn. Pbsn promoter-> Luc) (43) 
  Androgen deprivation in normal prostate, TAg, and JOCK models Tg(syn. Psa promoter -> Luc) (43) 
  
Androgen deprivation in normal prostate and TAg model Tg(Psa promoter-> Luc) (42) 
  
Androgen deprivation in normal prostate and TAg model Tg(Psa promoter-> Luc) (44) 
  
Δ16Her2 induced mammary gland dysplasia Tg(MMTV-Δ16Her2-IRES-Luc) (96) 
  
SV40 ER induced pancreatic cancer monitoring Tg(Rip1 promoter->SV40 ER-IRES-Luc) (97) 
  
Estrogen receptor activation Tg(Estrogen RE->Luc) (98) 
     Post-Transcriptional    
 ER Stress Tg(CMV->XBP1-STOP-SA-Luc) (55) 
    
Post-Translational 
   
  
Hypoxia Tg(Hypoxic RE->ODD-Luc) (62) 
  
Hypoxia KI(Rosa26 promoter->ODD-Luc) (61) 
  
Hypoxia, Neu/ Beclin1+/fl induced mammary gland dysplasia Tg(MMTV->neu; ODD-Luc); Beclin1fl/+ (60) 
     Protein-Protein Interactions 
  
  
Modular nuclear protein-protein interactions Tg(Gal4 promoter-> Luc) (64) 
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     Transformation 
   
 
Cre-Activation 
   
  
Cre Recombination Tg(Pomc promoter->Cre; Pomc promoter->Luc) (91) 
  
Cre Recombination Tg(β-actin promoter->flx-GFP-pA-flx-Luc-pA) (68), (71) 
  
Cre Recombination KI(Rosa26 promoter ->flx-STOP-flx-Luc) (99), (70) 
  
Cre Recombination Tg(CAG promoter->flx-STOP-pA-flx-TAg-Luc) (100) 
  
Cre Recombination 
                                                                                                        KI(Notch1 
promoter ->Notch1-Cre;->Notch1flx; Rosa26 promoter->flx-STOP-flx-CBR) (72) 
 
Tet-Regulated 
   
     
  
Coupled to MYCN expression Tg(Glt1 promoter->tTA; tet-o-Mycn-Luc) (79) 
  
TBX3 induced mammary gland dysplasia Tg(MMTV->rtTA;  tet-o-myc-Tbx3-IRES-Luc) (101) 
  
Wnt1 induced mammary adenocarcinoma Tg(MMTV->rtTA; tet-o-Wnt1-IRES-Luc) (102) 
  
PyMT induced pancreatic cancer monitoring Tg(Pdx1-rtTA; tet-o-PyMT-IRES-Luc) (78) 
PyMT induced pancreatic cancer monitoring Tg(Rip7 promoter->tTA;  tet-o-PyMT-IRES-Luc) (78) 
  
HPV16 E7 induced cervical cancer Tg(Krt5 promoter->rtTA; tet-o-Luc- E7) (103) 
 
 
Legend: 
Tg = transgenic mouse; KI= knock-in mouse; -> indicates promoter driving gene expression; RE = response elements multiple; TK= thymidine 
kinase; gene loci are separated by a semicolon (;). 
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Cancer Type Reporter Regulation Target Gene/ Process Investigated Reporter Strategy Ref. 
     
Brain 
    
 
Transcriptional Rb inactivation and tumor development in pituitary gland Tg(Pomc promoter-> Luc) (91) 
 
Transcriptional PDGF inactivation of Rb pathway Tg(E2f1 promoter->Luc0 (67) 
 
Transcriptional PDGF activation of Gli1/2 and gliomagenesis Tg(Gli1/2 responsive promoter-> Luc) (92)  
 Translational MYCN driven medulloblastoma Tg(Glt1 promoter->tTA; tet-o-Mycn-Luc) (79) 
  Prostate 
   
 
Transcriptional Androgen deprivation in normal prostate, TAg, and JOCK models Tg(Pbsn promoter-> Luc) (43)  
 Transcriptional Androgen deprivation in normal prostate, TAg, and JOCK models Tg(Psa promoter -> Luc) (43) 
 
Transcriptional Androgen deprivation in normal prostate Tg(Pbsn promoter + androgen response elements->Luc) (41) 
 
Transcriptional Androgen deprivation in normal prostate and TAg model Tg(Psa promoter-> Luc) (42) 
 
Transcriptional Androgen deprivation in normal prostate and TAg model Tg(Psa promoter-> Luc) (44)  
 
Cre Recombination Conditional Pten loss  Tg(β-actin promoter->flx-GFP-pA-flx Luc-pA) (71) 
 
Cre Recombination Conditional Pten loss  KI(Rosa26 promoter->flx-STOP-flx-Luc) (70) 
 
Transcriptional Systemic response to anti-androgen therapy Tg(Slp-androgen response elements -TK->Luc) (93) 
Liver 
    
 
Transcriptional Afp activation in DEN induced HCC KI(Afp promoter->TK-IRES-Luc) (94) 
 
Transcriptional Afp activation in DEN induced HCC Tg(Afp promoter -> Luc) (95) 
Breast 
    
 
Tet-on TBX3 induced mammary gland dysplasia Tg(MMTV->rtTA/; tet-o-myc-TBX3-IRES-Luc) (101) 
 
Transcriptional Δ16Her2 induced mammary gland dysplasia Tg(MMTV->Δ16Her2-IRES-Luc) (96) 
 
Transcriptional Neu, Beclin+/- induced mammary gland dysplasia KI(Rosa26 promoter ->ODD-Luc) (60) 
 
Tet-on Wnt1 induced mammary adenocarcinoma Tg(MMTV->rtTA; tet-o-Wnt1-IRES-Luc) (102) 
Pancreas 
    
 
Tet-on PyMT induced pancreatic cancer monitoring Tg(Pdx1-rtTA; tet-o-PyMT-IRES-Luc) (78) 
 Tet-off PyMT induced pancreatic cancer monitoring Tg(Rip7 promoter->tTA;  tet-o-PyMT-IRES-Luc) (78) 
 
Transcriptional SV40 ER induced pancreatic cancer monitoring Tg(Rip7 promoter->SV40 ER-IRES-Luc) (97) 
Lung 
 
Transcriptional Krasv12 induced lung tumorigenesis Tg(β-actin promoter->flx-GFP-pA-flx-Luc-pA) (68) 
Lymphoma 
    
 
Transcriptional B-cell lymphoma  KI(CD19 promoter->Luc) (50)  
Table II. Luciferase-Coupled Reporter Mice Utilized in GEMMs of Cancer. 
#
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Legend: 
Tg = transgenic mouse; KI= knock-in mouse; -> indicates promoter driving gene expression; RE = response elements multiple; TK= thymidine 
kinase; gene loci are separated by a semicolon (;). 
 
Cervical 
    
 
Tet-off HPV16 E7 induced cervical cancer Tg(Krt5 promoter->tTA; tet-o-Luc- E7) (103) 
     Spontaneous 
    
 
Transcriptional Ubiquitous TAg induced tumorigenesis Tg(CAG promoter->flx-STOP-pA-flx-TAg-Luc) (100) 
 
Cre Recombination Whole  animal stochastic  Notch1 loss of heterozygosity 
                                                                                     KI(Notch1 
promoter ->Notch1-Cre;->Notch1flx; Rosa26 promoter->flx-
STOP-flx-CBR)  (72) 
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Appendix B: DEVELOPMENT OF TUMOR-
MICROENVIRONMENT ACTIVATED ANTI-CANCER 
SALMONELLA 
B.1 Contribution to authorship 
  As second author on the following published manuscript, I performed in vitro and in vivo 
anti-tumor experiments and analyzed relevant data in addition to writing the complete 
introduction, discussion and respective results and methods sections.  Specifically, I personally 
cloned P1786-Stx2 anti-tumor vector and performed the in vitro toxicity experiments where in 
HeLa cells were incubated with conditioned media extracted from HeLa cells co-cultured with 
various genetically engineered Salmonella strains (Figure 5).  I also prepared the tumor cells, and 
bacteria for the in vivo bioluminescence imaging of the anti-tumor efficacy of P1787-Stx2 in 
addition to extracting and preparing the tumor for IHC as well as all data analysis (Figure 6).   
 
B.2 Published manuscript 
Flentie, K., Kocher, B., Gammon, S., Novack, D., McKinney, J. & Piwnica-Worms, D. A 
Bioluminescent Transposon Reporter-Trap Identifies Tumor-Specific Microenvironment-
Induced Promoters in Salmonella for Conditional Bacterial-Based Tumor Therapy. Cancer 
Discovery. 2012 Jul; 2(7):624-37. 
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Abstract 
  Salmonella specifically localize to malignant tumors in vivo, a trait potentially exploitable 
as a delivery system for cancer therapeutics. To characterize mechanisms and genetic responses 
of Salmonella during interaction with living neoplastic cells, we custom designed a promoterless 
transposon reporter containing bacterial luciferase. Analysis of a library containing 7,400 
independent Salmonella transposon insertion mutants in co-culture with melanoma or colon 
carcinoma cells identified five bacterial genes specifically activated by cancer cells: adiY, yohJ, 
STM1787, STM1791, and STM1793. Experiments linked acidic pH, a common characteristic of 
the tumor microenvironment, to a strong, specific and reversible stimulus for activation of these 
Salmonella genes in vitro and in vivo.  Indeed, a Salmonella reporter strain encoding a luciferase 
transgene regulated by the STM1787 promoter, which contains a tusp motif, showed tumor-
induced bioluminescence in vivo. Furthermore, Salmonella expressing Shiga toxin from the 
STM1787 promoter provided potent and selective anti-tumor activity in vitro and in vivo, 
demonstrating the potential for a conditional bacterial-based tumor-specific therapeutic. 
Statement of significance 
  Salmonella, which often encounter acidic environments during classical host infection, 
may co-opt evolutionarily conserved pathways for tumor colonization in response to the acidic 
tumor microenvironment. We identified specific promoter sequences that provide a platform for 
targeted Salmonella-based tumor therapy in vivo. 
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Introduction 
  The evolving and highly heterogeneous landscape of tumor genetics and the tumor 
microenvironment pose a significant challenge for treating advanced solid tumors (1).  Many 
characteristics of the tumor microenvironment, such as hypoxia, acidic pH, and a disorganized 
vascular architecture, limit delivery and efficacy of therapeutics and radiation treatments (2). 
Additionally, tumors undergoing targeted molecular therapy often relapse due to the utilization 
of autonomous parallel-redundant signaling pathways (3). Beyond the primary tumor, identifying 
disseminated disease that has metastasized to various organ sites is challenging, and systemically 
treating cancer often produces off-target toxicities. The ultimate anti-tumor therapy is one that 
overcomes these physiologic obstacles while simultaneously targeting tumors and avoiding 
normal tissue toxicity.  
  The remarkable ability of commensal and pathogenic bacterial strains to localize and 
preferentially grow within tumors has been well documented (4).  The immune-privileged, 
hypoxic and nutrient-rich ‘tumor soil’ facilitates colonization by facultative anaerobic bacteria 
(5).  These observations have spurred research into the diagnostic and therapeutic potential of 
genetically engineered and attenuated therapeutic strains of bacteria such as Salmonella, Listeria 
and Clostridium  (5).  Salmonella is one of the most studied of therapeutic bacteria, and upon 
systemic administration, is able to colonize xenograft tumors at rates 1,000 times greater than 
that of other organs, thereby abrogating tumor growth (6, 7). A firm understanding of the genetic 
programs involved in normal pathogenesis, characterization of spatiotemporal kinetics and 
dynamics during intra-tumoral colonization in vivo, genetic tractability, as well as the oncolytic 
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capacity of Salmonella typhimurium have made Salmonella strains ideal candidates for anti-
cancer bacterial development (8).  
  S. typhimurium by itself can illicit an anti-tumoral response through several potentially 
separate but synergistic mechanisms. First, as a pathogenic and cytotoxic bacterium, S. 
typhimurium can induce apoptosis of cancer cells (9). Second, pathogen-associated molecular 
patterns (PAMPs) of S. typhimurium, such as lipopolysaccharide (LPS) and flagellin, are capable 
of activating innate immunity by initiating pro-inflammatory TLR-MyD88/ TRIF-NF-κB 
signaling cascades (10).  Third, intracellular Salmonella flagellin can also enhance an anti-tumor 
adaptive immune response caused by the associative recognition with cancer cell antigen. The 
resulting signaling cascades ultimately augment antigen presentation by dendritic cells (DC), 
thereby promoting T cell clonal expansion and differentiation, which leads to an associative 
recognition of the cancer cell with the PAMPs of Salmonella (11, 12). Finally, despite the initial 
tumor regression, these tumors may eventually relapse, which has spurred the development of 
Salmonella as a delivery vehicle for anti-cancer co-therapies (13).  Indeed, Salmonella have been 
used as tumor-specific vectors for gene transfer of RNAi  or suicide genes, as well as targeted 
expression of apoptosis-inducing biologics, such as TRAIL, FASL and the bacterial toxin, 
Cytolysin A, all of which display pronounced anti-tumor affects in vivo (5). 
  However, few studies have investigated the specific genetic responses of Salmonella to 
tumor cells and bacterial mechanisms regulating these atypical “host” interactions. To address 
these quires, we engineered a bioluminescent transposon reporter-trap to screen a S. typhimurium 
library for genes specifically regulated by co-culture with malignant cells in vitro. Five genes 
were identified by the screen and their promoter sequences were found to be specifically 
activated by the acidic microenvironment associated with cancer cells in vitro and tumors in 
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vivo. Finally, we utilized the most pH-sensitive promoter sequence to demonstrate the utility of 
tumor-regulated Salmonella promoters to conditionally regulate the expression of a toxic tumor 
transgene in vitro and in vivo.  
 
Results 
A high-throughput screen to identify tumor cell-induced gene activation 
events in Salmonella. 
  To conduct a large-scale, unbiased screen for genes up-regulated by contact with 
malignant cells, we used a Tn5-based promoterless transposon as the backbone of a luxAB 
reporter construct. We chose to use the bacterial luciferase enzyme genes (luxAB) only, in 
contrast to the full bacterial luciferase operon (luxCDABE), because the size of the transposon 
containing the full operon prohibited efficient chromosomal integration, while using only the 
luxAB genes allowed for efficient genomic insertion of the transposon. The transposon was 
designed to restrict reporter gene expression to only those chromosomal integration sites 
downstream of an active promoter. A kanamycin resistance cassette with a constitutive promoter 
was also included to select for integration into the chromosome (Figure 1A). After construction, 
the purified transposon was electroporated into S. typhimurium strain SB300A1 (14) for random 
chromosomal integration, producing a 7,400 clone bacterial library.  
  Initially, the entire Salmonella library was subjected to a primary screen in the context of 
three conditions: tissue culture media alone, B16F10 melanoma cells and HCT116 colon 
carcinoma cells, both of the latter in monolayer co-culture with the Salmonella reporter library. 
The tumor cells were grown in 96-well plate format overnight and then bacterial clones added to 
wells corresponding to each of the two co-culture conditions and media alone. After a two-hour 
126 
  
incubation, bioluminescence imaging of plates enabled identification of clones specifically up-
regulating genes in the context of exposure to melanoma and/or colon carcinoma cells (Figure 
1A). Results of the screen from co-culture with melanoma and colon carcinoma cells are shown 
in Figures 1B and 1C, respectively. In each case, data are shown as a rank-ordered S-plot of the 
log2 of the normalized signal for each clone of the library, where normalized signal was the ratio 
of the signal in the condition of interest to the signal in media alone. The majority of data points 
clustered around zero, indicating that most mutants interrogated in the assay did not show tumor-
specific gene regulation. However, quartile analysis with a boundary for hit selection 
corresponding to a high stringency targeted error rate (α = 0.0027) identified five candidate 
mutants wherein the transposon reporter was specifically up-regulated during co-culture with 
malignant cells. 
Verification and characterization of Salmonella gene activation events in the 
context of tumor cell co-culture 
  Following the primary screen, we utilized inverse touchdown PCR to map the specific 
location of each transposon in the Salmonella genome (15). Table 1 documents the site of 
chromosomal integration for the transposon and candidate gene up-regulated in each isolate. All 
genes were novel in that they have not been previously reported to be involved in Salmonella-
host interactions, nor involved in Salmonella colonization of neoplasia. Interestingly, the 
genomic insertion sites of the transposon in three of the clones inserted in a cluster in the 
chromosomal sequence. Mapped to three different, but closely linked genes (STM1787, 
STM1791 and STM1793, respectively), two are known hydrogenases, and all three genes are 
likely co-regulated and involved in the same Salmonella function. Sequencing showed that in 
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one high stringency hit, the transposon had inserted into adiY, a Salmonella gene known to be 
involved in an acid tolerance response (16). The transposon in the fifth clone was identified to 
have landed in yohJ, a putative membrane protein (17). 
  To validate cancer cell co-culture-specific gene activation events identified in the primary 
screen, we first repeated the co-culture assay in quadruplicate in at least three independent 
experiments for each clone. Figure 2A shows the data from one representative experiment for 
clones verified by this assay. Again, all five clones showed statistically significant enhancement 
of bioluminescence in the presence of tumor cells, with a trend toward greater gene up-regulation 
when co-cultured with B16F10 melanoma cells. Then, to further characterize tumor cell-induced 
response of Salmonella, we utilized the tumor cells in a dose-response assay (Figures 2B, C). 
Additionally, to verify that reporter activation seen in the Salmonella reporter-trap clones was 
not an effect of differing substrate permeability due to mutations in bacterial genes, bacteria were 
generated that contained the original chromosomal luxAB insertion as well as a plasmid 
constitutively expressing luxCDE, the biosynthetic genes for the long-chain aldehyde that acts as 
the optical substrate of the bacterial luciferase operon. Therefore, for this assay, it was not 
necessary to add decanal to the media. Identical inoculations of bacteria showed greater up-
regulation of the reporter when exposed to greater numbers of tumor cells in co-culture 
conditions, indicating that the stimuli from tumor cells instigated a graded response from the 
bacteria. Because expression of the lux operon genes fully complemented the use of exogenous 
decanal in the system, the data confirmed that the effect was not an artifact of exogenous decanal 
permeability in the primary screen.  
  Finally, to verify that the reporters in fact reflected mRNA transcriptional regulation in 
wild-type Salmonella during co-culture with tumor cells, we utilized semi-quantitative PCR. 
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Following a three-hour co-culture of wild-type (SB3001A1) bacteria with B16F10 cells or in 
tissue culture media alone, isolated RNA was reverse transcribed to cDNA. Semi-quantitative 
PCR of cDNA showed that co-culture with B16F10 melanoma cells enhanced the intensity of 
target gene transcripts, but not control ribosomal RNA transcripts (rrsH) (Figure 2D). The effect 
was generalizable, as co-culture with HeLa tumor cells produced similar results (Figure 2D). 
Notably, of the genes identified in this screen, at least one, adiY, has previously been 
reported to be up-regulated in acidic pH conditions (16). One characteristic of tumor 
microenvironments in vivo is an abnormally acidic pH (18). In fact, due to the Warburg effect, 
cancer cells are constitutively glycolytic, even in high oxygen conditions, releasing lactic acid 
and thereby creating a particularly acidic tumor microenvironment (19).  For these reasons, the 
Salmonella transposon insertion mutants were further investigated for reporter signal activation 
in acidic conditions. Figure 3A shows that reporter signals increased in acidic pH media 
compared to neutral media. Each of the clones up-regulated the reporter gene at pH 6.0 
compared to the physiological pH of normal body tissue (pH 7.5), suggesting that the stimulus 
Salmonella responded to in the context of neoplastic cells was microenvironment acidification. 
To determine whether the activated genes were required for localization to tumors or 
required for colonization and growth within tumors in vivo, Salmonella strains null for genes 
identified in the screen were constructed. Selected genes were deleted using a lambda red 
recombinase insertional deletion strategy, which inserted a chloramphenicol resistance cassette 
into the targeted genes. The deletion mutants were created from a parental Salmonella strain 
(luxCDABE msbB-) containing a chromosomally-integrated and constitutively-expressed 
bacterial luciferase operon for imaging bacterial localtization in vivo in real time. The strain also 
contained a msbB gene deletion, which causes a less immunogenic LPS structure and minimizes 
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septic shock effects when the strain is administered intravenously (20). Based on the analysis 
that the identified STM1787, STM1791 and STM1793 genes were contained in a single operon, 
we targeted a large region of this operon for deletion in a single mutant strain, 1789
-
1793
-
. The 
gene adiY also appeared to be a part of a larger operon of co-regulated genes and was therefore 
targeted along with the adjacent genes adi and yjdE. The gene yohJ was targeted individually. In 
a B16F10 melanoma tumor xenograft model, all bacterial strains were injected via mouse tail 
vein and deletion mutants compared to the parental strain for localization to and persistence 
within the tumor using bioluminescence imaging (Supplementary Figure 1). All mutant strains 
and the parent strain were capable of tumor localization and persistence, indicating that although 
the identified genes were activated by tumor cell co-culture in vitro, they were not essential for 
bacterial colonization of the tumor. The experiment was also performed in an HCT116 colon 
carcinoma xenograft model with similar results. Supplementary Table 1 summarizes the 
numbers of mice with colonized tumors on or before day 10 in each experiment. Additionally, in 
pilot competitive infection studies, there was no significant difference between the STM1789-
1793 mutant and the parental Salmonella strain (luxCDABE msbB-) in tumor colonization 
(CFU/ml; data not shown). 
Specificity and reversibility of the Salmonella STM1787 promoter in vivo 
We next sought to demonstrate the specificity of the STM1787 promoter activation in the 
tumor microenvironment in vivo. We chose this promoter because it displayed the highest acidic 
pH induction in vitro (Figure 2A).  Here, we used the constitutively bioluminescent Salmonella 
strain Tn:27.8+pluxCDE or the conditionally bioluminescent strain Tn:1787+pluxCDE, each of 
which constitutively express plasmid-encoded luxCDE, but the latter strain will only 
bioluminesce upon activation of the chromosomally-encoded luxAB reporter. In a B16F10 
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melanoma tumor xenograft model, bacteria were injected via mouse tail vein or intratumorally 
and allowed two days to localize and adapt to tumors in vivo. Tumors were then excised, 
incubated in solutions of various pH values and imaged periodically for six hours. Initially, all 
tumors showed bioluminescent bacteria ex vivo. Over time, constitutive Tn:27.8 Salmonella 
showed a gradual increase in signal consistent with bacterial growth in the tumor explants. This 
behavior was also observed in the Tn:1787 Salmonella-infected tumor explants incubated in low 
pH media. By contrast, when the Tn:1787 Salmonella-infected tumor explants were maintained 
in basic media conditions throughout, the signal initially increased, but then plateaued around 4 
hours and decreased in comparison to the constitutively bioluminescent Tn:27.8 strain (Figure 
3B,C). This finding suggested that bacterial gene expression was initially engaged by the low pH 
conditions of the in vivo tumor microenvironment, but after exposure to a higher pH environment 
ex vivo, the promoter driving the reporter was repressed and signal declined. Further, this ex vivo 
effect was reversible. When the medium on the Tn:1787 Salmonella-infected tumor explant was 
changed from pH 6.0 to pH 7.5, the bioluminescent signal decreased. Conversely, when the 
media was changed from pH 7.5 to pH 6.0, the signal increased (Figure 3B, C). These effects 
were not seen with the constitutive Tn:27.8 Salmonella-infected tumor explants, and provided 
further evidence in support of the specificity of the trapped Salmonella promoter in the Tn:1787 
transposon mutant for the tumor microenvironment.  
Because the identified promoters were highly activated in the tumor microenvironment ex 
vivo, utilization of these promoters provided a unique opportunity to design tumor-targeting 
bacterial vectors subject to multiple levels of controlled specificity in vivo. Thus, we sought to 
determine if the acidic pH of the tumor microenvironment could be exploited to specifically 
activate a target transgene during tumor localization. As proof of principle, we constructed 
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Salmonella reporter strains expressing plasmids encoding the bacterial luciferase operon driven 
by either constitutive promoters or an inducible promoter to demonstrate tumor-mediated 
transgene activation in vivo. The plasmids pMAAC001 and pLux both encoded constitutively-
expressed luciferase operons, while the pPROMOTERLux plasmid was engineered to contain the 
luciferase operon driven by the Salmonella candidate promoter (STM1787) comprising 500 base 
pairs upstream of the putative transcription start site of tumor-activated genes STM1787, 
STM1793 and STM1791 (which we will now refer to as the STM1787 promoter). Bacteria 
expressing these plasmids were identically injected into mice bearing HCT116 tumor xenografts 
on each flank (Figure 4). We chose to utilize intratumoral injection to directly compare reporter 
gene activation from two different bacterial strains, one inducible and the other constitutive, over 
time in the same mouse. Although reporter signals from pPROMOTERLux-expressing bacteria 
were low immediately after injection into the tumor, the bacteria quickly induced a 90-fold 
enhanced expression of the reporter after an 8 hr exposure to the tumor microenvironment 
(Figure 4A). Concurrently, bacteria constitutively expressing pLux- or pMAAC001-luciferase 
showed <20-fold or no reporter activation, respectively, after exposure to the tumor 
microenvironment (Figures 4A and 4B). These data directly demonstrated tumor-specific 
induction of a transgene from the Salmonella STM1787 promoter in an in vivo system. Therefore, 
the STM1787 promoter could be used as a platform to design tumor-targeting Salmonella strains 
capable of specifically delivering a therapeutic gene or toxin to the site of a tumor in vivo. 
Selective anti-tumor therapy in vivo 
We utilized the cancer cell-activated STM1787 promoter to regulate the expression of 
Shiga toxin 2 (Stx2), a toxic transgene of bacterial origin, in a wild type strain of S. typhimurium 
(SB300A1) to selectively induce tumor cell death in vitro and in vivo.  Stx2 is a secreted AB5 
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holotoxin composed of a single N-glycosidase A subunit that is directed to target eukaryotic cell 
membranes through interaction of the pentameric B subunits and the host receptor, 
glycosphingolipid globotriaosylceramide (Gb3) (21).  Once inside the host cell, the A subunit 
cleaves the 28S RNA of the 60S ribosomal subunit, thereby inhibiting peptide elongation and 
inducing apoptosis. Stx2B has been extensively studied for its tumor targeting potential as many 
invasive tumors display high levels of Gb3 (22). 
Using bioluminescence as a reporter of total tumor cell mass, we performed a co-culture 
experiment with HeLa
CMV-Fluc
 cells in vitro. First, plated HeLa cells were grown to confluency to 
acidify the media and then co-cultured with strain SB300A1 transformed with P1787 (empty 
vector) or P7187-Stx2. Both SB300A1 transformants were also grown in media alone.  The 
supernatant was then filtered from each of the groups and aliquoted onto separately plated 
HeLa
CMV-Fluc
 cells in increasing volumes: 1) +media+P1787; 2) +media+P1787-Stx2; 3) 
+HeLa+P1787; and 4) +HeLa+P1787-Stx2. After 24 hours of treatment, major toxicity was only 
observed in HeLa
CMV-Fluc 
cells treated with the supernatant of +HeLa+P1787-Stx2 (Figure 5A); a 
general concentration-response trend was observed (Figure 5B). Stx2 expression was verified 
using mRNA PCR amplification (Figure 5B inset).  No overt cytotoxicity was observed in 
HeLa
CMV-Fluc
 cells treated with supernatant from any of the other conditioned media groups.  
      Given the selective regulation and associated toxicity of P1787-Stx2 in vitro, we next 
desired to demonstrate the tumor-targeting potential in vivo using established s.c. flank HeLa
CMV-
Fluc
 xenograft tumors and bioluminescence imaging.  In two independent proof-of-principle 
experiments, intratumoral injection of a single high-dose of SB300A1 transformed with P1787-
Stx2 resulted in an 80% mean reduction in initial viable tumor mass five days after treatment 
(Figure 6A).  Furthermore, when tumors were treated with a single low-dose of SB300A1 
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transformed with P1787-Stx2, a robust anti-tumoral effect was observed after two weeks (Figure 
6B). We also observed that treatment with P1787 resulted in tumor stasis, consistent with 
previous reports that S. typhimurium alone can block tumor growth in vivo, while LB broth alone 
showed no inhibitory effect (23).  To verify tumor cell death independent of bioluminescence 
signal, tumor H&E sections from the high-dose treatment were analyzed (Figure 6C). Sections 
through LB-treated (control) tumors showed a broad rim of viable tumor cells with focal necrotic 
regions centrally.  In the P1787 tumors, a thin rim of viable tumor cells was present in most 
areas, with fibroinflammatory reaction at the periphery of the mass.  The central necrotic zone 
was larger and contained more neutrophils than in the LB-treated tumors.  In the P1787-Stx2-
treated tumors, viable tumor cells were difficult to find, and in most sections, only a central 
necrotic zone surrounded by fibroinflammatory reaction was present. Note that mice treated with 
high-dose P1787-Stx2 eventually succumbed to the combined bacterial and Stx2 toxin load.  
However, mice receiving low-dose P1787-Stx2 were healthy for two weeks, at which point the 
experiment was concluded, but each still displayed a significant reduction in tumor size 
compared to P1787 alone (Figure 6B).  
 
Discussion 
Salmonella typhimurium bacteria are typically classified as human gastrointestinal 
pathogens and a common cause of modern food-borne illness. However, another noted 
characteristic of Salmonella is the capacity to colonize tumor tissue. In fact, in the 1800’s, 
physicians began to intentionally use bacteria as tumor therapeutics, but due to significant 
toxicity and lack of consistent, reliable results, these practices were abandoned. However, 
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modern studies using attenuated strains and longitudinal imaging have demonstrated colonization 
of tumors by Salmonella in real time and have sparked a renewed interest in this concept using 
Salmonella (23, 24) as well as various other tumor-localizing microbes as an option for cancer 
treatment (25-31). These observations along with the current intense focus on developing PAMP/ 
TLR-based anti-cancer immunotherapies offer unique opportunities for combinatorial strategies 
in tumor targeting. 
Both wild-type and genetically engineered Salmonella are capable of inducing tumor 
regression in mouse cancer models (4), as was observed in our experiments (Figure 6).  A 
number of studies utilize bacteria as treatment vectors per se or as drug delivery vehicles by 
exploiting their potentially low toxicity and high genetic tractability to maximize therapeutic 
efficacy  (5). In this regard, various attenuated Salmonella strains have been developed for use in 
tumor-targeting studies, including specific amino acid auxotrophs and LPS mutants (20, 32). 
However, the greatly reduced toxicity of Salmonella LPS mutants (msbB-) observed in swine 
models has not been observed in mouse models (33, 34). In more than one instance, attenuated 
Salmonella have even been used in a clinical trial to treat cancer in humans (35, 36). However, 
trials so far show relatively low rates of tumor colonization in human hosts, which may be due to 
excessive attenuation of the bacterial strains (5, 34). Indeed, one study indicates that induction of 
TNFα by bacteria is necessary for optimal colonization of tumors (37). Nonetheless, few studies 
have investigated the phenotypic and gene expression patterns of these tumor-targeting bacteria 
following exposure to tumor cells. 
In this study, we utilized an engineered transposon to interrogate the Salmonella genome 
for genes activated during exposure to cancer cells. Toward this objective, we generated a library 
of greater than 7,400 independent transposon insertions, which, assuming random integration, 
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would predict genomic transposon insertion into each of Salmonella’s 4,620 genes at least once. 
From this library, we identified five Salmonella genes specifically up-regulated during co-culture 
with cancer cells: STM1787, STM1791, STM1793, adiY and yohJ. Following identification of 
these tumor cell-activated genes, verification in secondary assays and confirmation in wild-type 
Salmonella, we determined that the common stimulus for up-regulation of target gene expression 
was acidic pH. In another study aimed at identifying Salmonella promoters involved in tumor 
colonization in vivo, Salmonella genomic DNA was digested and ligated randomly upstream of a 
GFP reporter. In this study, the major stimulus identified in reporter activation was hypoxia, but 
no pH-regulated promoters were identified (38).   Another recent study performed a similar in 
vivo screen utilizing a promoter-trap GFP based system and indentified a conserved ‘tumor 
specific’ DNA motif (tusp) in the promoters of Salmonella genes specifically activated in a 
tumor xenograft model (33).   While pH and hypoxia are physiologically linked, the five genes 
identified herein show no overlap with the promoters identified by Leschner et al. (33) nor 
Arrach et al. (38). However, the STM1787 promoter located upstream of three of our own target 
genes (STM1787, STM1791, and STM1793) did contain the conserved tusp motif identified by 
Leschner et al. (tattttatataaa). The discrepancy in promoter identification may stem from the 
different bacterial strains or strategies utilized for gene identification in the two studies.  
Whereas Arrach et. al. utilized a plasmid-based overexpression system, the present study 
identified genes by chromosomal integration of a transposon.  Nonetheless, hydrogenase genes 
are noted in some cases to be up-regulated in low oxygen conditions, indicating that hypoxia 
may serve as a further stimulus for the pH-induced promoters identified in the present study (39). 
However, in pilot studies with an incubation pouch system used for growing anaerobic bacteria, 
we did not observe any significant changes in transposon reporter activity under hypoxic 
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conditions (KF, unpublished data). While these data do not necessarily rule out oxygen-
independence, pH appeared to be the dominant signal inducing responses in the promoters 
identified by our bioluminescent transposon reporter-trap screen.  It will also be of interest in 
future studies to determine if in addition to hypoxia, pH is another regulator of Salmonella 
promoters that contain the largely uncharacterized tusp motif.  
In view of the usual pathophysiology of Salmonella, it is not surprising that Salmonella 
strains have gained the ability to precisely regulate genes in response to different pH 
environments. Salmonella encounter low pH conditions regularly during human infection, for 
example, during transit through the stomach, and later during intracellular trafficking through the 
phagosome (40, 41). Interestingly, the acidic pH of the tumor environment in vivo has long been 
noted as an important microenvironmental condition when designing effective tumor treatments 
(18, 42). Additionally, the low pH environment of the tumor inhibits host defense. Cytotoxic 
immune cell activity and cytokine secretion has been shown to be impaired by a low 
extracellular pH (43). In contrast, with a bacterial-driven tumor therapeutic, low pH may become 
an exploitable advantage, by adding another level of selectivity to bacterial gene activation. 
Indeed, the utility of a low pH-activated bacterial therapeutic will avoid toxicity to the liver and 
spleen which are the other major off-target organ sites of bacterial colonization, but which 
generally have a neutral pH (33). In this case, a bacterial-based system may succeed, while both 
conventional therapeutics and host defenses fail.  
When using bacteria as a vector for drug delivery studies, tumor-specific colonization 
and subsequent expression is a major concern. The genes identified herein are highly expressed 
in an acidic tumor environment, but are not required for bacterial tumor targeting (Supplemental 
Figure 1). Therefore, the promoters regulating these genes and further dissection of the complex 
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regulation of the tusp motif may generate ideal chromosomal insertion site candidates or 
synthetic promoter systems for utilization in therapeutic gene, pro-drug or toxin delivery studies. 
We have identified the STM1787 promoter as an ideal bacterial sequence capable of driving 
tumor-specific expression of a transgene, and demonstrated this in vivo using bioluminescent 
imaging. We further applied the STM1787 promoter to conditionally regulate the expression of 
Stx2 in wildtype S. typhimurium in tumor targeting toxicity models in vitro and in vivo. In proof-
of-principle studies, we observed dramatic cancer cell death in a co-culture model in vitro and 
dramatic tumor response over a relatively short time scale with a robust therapeutic effect in 
vivo.  Future pharmacokinetic studies with P1787-Stx2 will be required to optimize mode of 
delivery, dose, and efficacy. In addition, it will be of interest to take advantage of the recent 
discovery that manganese treatment protects the host against lethal levels of Shiga toxin (44). 
Clearly, other relevant tumor toxins could be explored downstream of STM1787.  
In summary, by adapting the STM1787 promoter in Salmonella to drive expression of an 
appropriate therapeutic transgene, the resulting bacterial vector would provide two independent 
mechanisms for specifically targeting tumors. First, Salmonella specifically localize to and 
accumulate in primary tumors and metastases in vivo. Second, the STM1787 promoter is 
preferentially activated in the acidic tumor microenvironment. The combined effect of these two 
levels of specificity provides a potential option to design more successful PAMP/ TLR-based 
immunotherapeutic bacterial systems in the future.  
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Methods 
Bacterial strains and culture conditions  
The Salmonella typhimurium strains SB300A1 (14), SB300A1FL6 (luxCDABE) (45), luxAB and 
AM3 (luxCDABE msbB-) were grown in LB broth with appropriate antibiotics. SB300A1FL6 is 
modified by chromosomal integration of luxCDABE and is constitutively bioluminescent. The 
luxAB strain consists of SB300A1FL6 with the integrated luxE gene disrupted. This strain does 
not bioluminesce without addition of exogenous decanal substrate. The AM3 strain has the 
SB300A1FL6 background, but also has an msbB gene disruption, giving it a less immunogenic 
LPS structure. The Tn:27.8 strain, specifically identified from the screen as a non-inducible 
mutant, phenocopies luxAB with constitutive bioluminescence that requires exogenous decanal. 
Tissue culture cell lines and culture conditions 
 B16F10 murine melanoma and HeLa cells were obtained from ATCC and cultured according to 
ATCC directions. HCT116 human colon carcinoma cells were a gift from Bert Vogelstein and 
were cultured according to ATCC methods. Cell lines were not further authenticated. 
Plasmids:   The plasmid pMAAC001 contains the full bacterial luciferase operon luxCDABE 
driven by a T7 promoter and an ampicillin resistance cassette. The plasmid pLuxCDE consists of 
the pMAAC001 backbone amplified using the forward primer cccgggattggggaggttggtatgtaa and 
the reverse primer cccgggtgaatgatttgatgagccaaa (XmaI sites underlined). This product was then 
XmaI digested and re-ligated to exclude the majority of the luxA and luxB genes. pLux and 
pPROMOTERLux plasmids were constructed by inserting the full bacterial luciferase operon 
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between the KpnI and BamHI restriction sites in the vector pUC19. The pPROMOTERLux 
plasmid additionally had a 500 base pair promoter region (STM1787) from the Salmonella 
genome inserted upstream of the luciferase operon between the SacI and KpnI restriction enzyme 
sites. The 500 base pair sequence was amplified from the Salmonella genome using the forward 
primer aaagagctcacgccctctttcaaacagtc and the reverse primer aaaggtaccgcttgataaaaggtctcctcgt 
(SacI and KpnI sites underlined).  To construct the P1787-based vectors, 500bp of the 
endogenous SB300A1 1787 promoter was cloned into the BglII and NdeI sites of pET3a 
(Novagen) using the following primers: forward-gagagagaagatct gggacgccctctttcaaacagtctc, 
reverse- ccttcctgcccatatgaacgcgtattttttctcctttttgcacc. This cloning strategy conserved the 
endogenous 1787 Shine-Dalgarno sequence and removed the T7 promoter and synthetic RBS of 
pET3a. The P1787-Stx2A/B vector was constructed by inserting the Stx2A/B operon downstream 
of the 1787 promoter using NdeI and BamHI with the following primers: forward-
gagagagacatatgaagtgtatattatttaaatgggtactgtgcctgttactgggtttttcttcggtatcc, reverse- 
ccttccttccggatccttatcaatggtgatggtgatggtgg.  
Construction of a Salmonella typhimurium reporter-trap library   
Salmonella strain SB300A1 was used to construct a bacterial library comprising approximately 
7,400 clones of unique chromosomal integrations of our reporter transposon (14). The custom 
Tn5-based transposon was designed with the EZ-Tn5 system (Epicentre, Madison, WI) using the 
pMOD4 transposon construction vector. A kanamycin-resistance cassette and promoter from EZ-
Tn5<KAN-2> was amplified using the forward primer acgacaaagcttggacgcgatggatatgttct and the 
reverse primer agcttttctagaggtggaccagttggtgattt (HindIII and XbaI restriction sites underlined) 
and inserted into the HindIII and XbaI restriction sites of pMOD4. The luciferase enzyme genes 
luxAB from Photorhabdus luminescens were amplified with the forward primer 
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acagtcgaattccgccgaatgagaattgagat and the reverse primer aagctgggtacctgttggctgctttcactcac 
(EcoRI and KpnI sites underlined) and inserted between the EcoRI and KpnI sites in pMOD4 
(45). The plasmid contained an R6Kγ origin of replication and therefore was amplified in E. coli 
DH5α λpir, purified, digested with PvuII, and the transposon fragment recovered by gel 
purification. The purified transposon was combined with transposase (Epicentre). After bench 
top incubation for 30 minutes, followed by 48 hours at 4°C, the transposon DNA was 
electroporated into bacteria as per the vendor’s instructions. Bacteria were plated on LB 
kanamycin plates to select for transformants containing the chromosomally-integrated 
transposon. Each clone was expanded and stored in 60% glycerol in 96-well plates at -80°C. 
Screening the library   
To screen for gene activation events occurring in the context of malignant cells, Salmonella 
library clones were cultured under three different conditions: co-culture with B16F10 mouse 
melanoma cells, co-culture with HCT116 human colon carcinoma cells and culture in media 
alone. Each of the two tumor cell lines were seeded into 96-well white plates at approximately 
70-80% confluency in DMEM with 10% FBS. In the plate containing media alone, each well 
contained 100 μl of DMEM with 10% FBS only. Plates were incubated overnight to allow tumor 
cell adhesion to the 96-well white plates. Independently, bacterial clones were grown overnight 
in LB broth with kanamycin in 96-well plates and subcultured the following day 1:10 into LB 
broth. Five to six hours after subculturing, 30 μl of bacterial culture were added to three replicate 
plates, each corresponding to a separate culture condition. Bacteria were allowed to co-incubate 
with the malignant cells or media alone for 2 hours. Subsequently, bacteria were imaged by 
adding 30 μl of decanal solution, waiting 10 minutes, and imaging with an IVIS 100 imaging 
system (Caliper; acquisition time, 60 sec; binning, 4; filter, < 510; f stop, 1; FOV, 23 cm) (46). 
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Because white plates were used to maximize signal intensity, images were aquired utilizing a 
<510 filter to reduce phosphorescence from the plates. Three control wells were included on 
every plate comprising:  luxCDABE Salmonella (SB300A1FL6), which contain the full 
luciferase operon inserted into the chromosome; luxAB strain, which contains the luciferase 
enzyme genes only and therefore requires addition of exogenous substrate to image reporter 
activity in the assay; and a blank well, which contained media, but was not inoculated with 
bacteria, to serve as a control for background luminescence. Imaged plates were analyzed with 
Living Image (Caliper) and Igor (Wavemetric) analysis software packages as described (47). 
Data were normalized by dividing the photon flux of experimental wells by media alone wells 
and presented as the log2 of the normalized photon flux data. 
Identification of hits  
Library screening data representing photon flux from each well of a library plate were analyzed 
with Image J software (48). To identify statistically significant hits from the primary screens, we 
utilized a set of statistical requirements. First, a threshold was set to identify active clones. 
Clones that did not produce photon signals greater than three standard deviations above the 
signal in the un-inoculated, media alone wells were not further analyzed. A quartile method of 
statistical analysis was then applied to the remaining clonal data (49). For quartile analysis, 
plates of clones were grouped by assay date into sets for data analysis. For each set, we 
normalized data by calculating the log2 of the fold-change of photon flux signal between the 
condition of interest (co-culture with B16F10 or HCT116 cells) and media alone. From this data, 
we calculated the median (Q2), first (Q1), and third (Q3) quartile values. The boundary for hit 
selection was calculated as Q3 + c(ICQ), where ICQ = Q3-Q1 and c = 1.7239, corresponding to 
a high stringency targeted error rate of α = 0.0027 (49). 
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Verification of primary screen hits 
 To verify hits identified by the primary screen, clones were tested again in a similar manner, in 
quadruplicate. The assay followed the same steps as those in the primary screen, except each 
clone was tested in 4 wells under each of three conditions across a 12-well row in a black 96-
well plate. Imaging was done with an IVIS 100 imaging system (acquisition time, 60 sec; 
binning, 4; filter, open; f stop, 1; FOV, 23 cm). 
Identification of transposon insertion site 
 To map sites of transposon integration in the chromosome of clones of interest, an inverse 
touchdown PCR strategy was used (15). Genomic DNA was isolated from bacteria using 
DNAzol (Molecular Research Center, Cincinatti, Ohio). PCR was performed using bacterial 
chromosomal DNA, 20 pmols of a primer specific to the 5’ end of the transposon 
(atggctcataacaccccttg), and 100 pmols of a degenerate primer (cggaatccggatngayksnggntc). 
Reactions were initiated with a 95°C preparation step for 5 minutes, followed by 25 cycles 
comprising denaturation at 95°C for 45 seconds, annealing at various temperatures for 45 
seconds and extension at 72°C for 2 minutes. The annealing temperature started at 60°C and 
decreased 0.5°C per cycle for the subsequent 24 cycles. Then PCR proceeded with 25 cycles of 
95°C for 45 seconds, 50°C for 45 seconds and 72°C for 2 minutes. PCR reaction products were 
fractionated on a 1% agarose gel, and the most prominent bands in each lane were excised and 
gel purified (Qiagen kit). For some reactions, PCR products were purified (Qiagen) and the 
resulting purified PCR product was used as a template for a second round of PCR using a 
different transposon-specific primer (aacatcagagattttgagacacc) before gel purification of 
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products. The cycling conditions and degenerate primer used in the second round of PCR were 
the same as round one.  
Semi-quantitative RTPCR  
Salmonella strains SB300A1, P1787 or P1787 transformed SB300A1 were subcultured from a 
stationary phase culture 1:10 and grown for 6 hours. Bacteria were then diluted 1:20 and 30 μl 
added to 96-well plates containing tissue culture media alone,  B16F10 melanoma cells or HeLa 
cells, seeded 24 hours previously at 100,000 cells/well and 50,000 cells/ well, respectively. After 
three and a half hours of co-culture, extracellular media containing bacteria was removed from 
the 96-well plates and triplicates pooled. Media were centrifuged to pellet bacteria and pellets 
were frozen at -80°C. After thawing, pellets were resuspended in 200 μl water with 5 mg/ml 
lysozyme and incubated at room temperature for 5 minutes. Then, 700 μl of RLT buffer was 
added and bacterial RNA was purified using the Qiagen RNeasy kit (Qiagen Inc, Valencia, CA). 
Samples were then treated with DNase I at room temperature for 15 minutes, after which EDTA 
was added and samples were incubated for 10 minutes at 65°C to inactivate the DNase. Samples 
were then ethanol precipitated and resuspended in 30 μl water. For reverse transcriptase PCR, 1 
μg of total RNA was used as a template and reverse transcribed using Superscript II Reverse 
Transcriptase and 300 ng random primers as per the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA). Following RTPCR, samples were treated with RNase H for 25 minutes at 37°C. 
To perform semi-quantitative PCR, samples were amplified using primers specific to each gene 
target or to ribosomal RNA: STM1787 (forward: tcggtagatcgcatgatgtc, reverse: 
ggttggtcataagcctgtcg), STM1791 (forward: acacgggaacatccagattc, reverse: 
cggcaaaggacaaatctcat), STM1793(forward: ttcggcaacctgtttttagg, reverse: acgcctccttgcataatcac), 
adiY (forward: ccttattgaccgccaactgt, reverse: gtggtcaagaaagcgggata), yohJ (forward: 
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caggcatttttcttgcatca, reverse: cgccatataacgaatcagca), rrsH (forward: cagccacactggaactgaga, 
reverse: gttagccggtgcttcttctg), Stx2A (forward: atgacgccgggagacgtgga, reverse: 
ggccacagtccccagtatcgct) and Stx2B (forward: gcaatggcggcggattgtgc, reverse: 
acaatccgccgccattgcat). PCR cycling conditions were: 95°C for 5 minutes, 30 cycles (or 20 cycles 
for rrsH reactions) of denaturation at 95°C for 45 seconds, annealing at 50°C for 45 seconds and 
extension at 72°C for 1 minute. PCR products were fractionated on a 1% agarose gel.  
Construction of deletion mutants  
Mutant strains deficient for the identified target genes were constructed in Salmonella strain 
luxCDABE msbB- (AM3), which contains a constitutively active, chromosomally-encoded 
bacterial luciferase operon as well as a mutation in msbB to create a less immunogenic LPS 
structure. Mutants were constructed using a lambda red recombinase strategy (50). First, primers 
were designed to amplify the chloramphenicol-resistance cassette in pKD3 with tails flanking the 
targeted locus of the Salmonella genome to be deleted. Primer sequences specifically targetting 
the genome for each mutant were used (adi forward  targetting  primer:  
atgaaagtattaattgttgaaagtgagtttctgcatcaggacacctgggtgtgtaggctggag-ctgcttc, adi reverse targetting 
primer:  atcctgtttaaccggcgcatccagcggatacgggtttttgtgaatgc-ggtcatatgaatatcctccttag; yohJ forward  
targetting  primer:   agtaagtcactgaatattatctg-gcaatatatacgcgcttgtgtaggctggagctgcttc, yohJ reverse  
targetting  primer:   ttttttcgttcc-cttctgcccaaccactttacgctcaccgcatatgaatatcctccttag; STM1789-1793 
forward  targetting  primer: atgaatgcgcaacgcgtagtggtgatggggttaggaaaccgtgtaggctggagctgcttc, 
STM1789-1793 reverse  targetting  primer: ctaataaagttcatgatcgttgcggcggagggtccccaggcatatgaa-
tatcctccttag). PCR fragments were then electroporated into AM3 bacteria expressing plasmid-
encoded red recombinase. Following electroporation, growth on chloramphenicol plates at 37°C 
selected for strains that had lost the temperature-sensitive recombinase plasmid and inserted the 
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chloramphenicol-resistance cassette into the targeted genomic loci. Deletion of the genes was 
confirmed by PCR.  
Dose-response to tumor cells  
To test the dose-response of hits from the screen to tumor cell co-culture, the assay was 
performed as described, except that either B16F10 or HCT116 cells were plated at 1x10
5
; 2 x10
5
; 
or 3 x10
5
 cells per well 24 hours before co-culture with bacteria. Stationary phase bacteria were 
diluted 1:50 and incubated for 6 hours before identical aliquots were allowed to co-culture with 
the malignant cells. Growth curves performed for each mutant strain at different pH values 
showed no significant differences. Imaging was done with an IVIS 100 imaging system 
(acquisition time, 10 sec; binning, 8; filter, open; f stop, 1; FOV, 20 cm). Imaged plates were 
analyzed with Living Image (Caliper) and Igor (Wavemetrics) analysis software packages as 
described (47). 
Assaying promoter activation in different pH media  
Stationary phase bacteria were subcultured 1:100 into LB broth. Five to six hrs after 
subculturing, 10 μl of bacterial culture were added to 190 μl pre-warmed HEPES-buffered media 
in black 96-well plates  adjusted to different pH values, and allowed to incubate for three and a 
half hours. Bacteria were then imaged with an IVIS 100 imaging system (acquisition time, 60 
sec; binning, 8; filter, open; f stop, 1; FOV, 20 cm).  
Mouse imaging studies 
To generate tumor xenografts, 6-week old nu/nu mice (Taconic) were injected subcutaneously in 
the right flank with 1 x10
6
 B16F10 cells or 2.5 x10
6
 HCT116 cells in 100 μl PBS. Tumors were 
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allowed to grow for two (B16F10) or three (HCT116) weeks before bacterial challenge. 
Saturated cultures of strain AM3 and deletion mutant bacteria were subcultured 1:100 into LB 
and grown for 3 hours. Bacteria were then diluted to 1 x10
6
 bacteria/ ml (based on OD600 
readings) and 100 μl were injected via tail vein. Mice were imaged as indicated using an IVIS 
100 imaging system (acquisition time, 60 sec; binning, 8; filter, open; f stop, 1; FOV, 20 cm). 
Photon flux data were calculated by utilizing user-determined regions of interest (ROIs) around 
bioluminescent tumors with Living Image software.  
For in vivo promoter inducibility experiments, 6-week old nu/nu mice (Taconic) were injected 
subcutaneously in the right and left flanks with 1 x10
7
 HCT116 cells in 100 μl PBS. Tumors 
were allowed to grow for one week. Saturated cultures of Salmonella strain SB300A1 containing 
plasmids pMAAC001, pPROMOTERLux, or pLux were subcultured 1:100 into LB and grown 
for 3 hours. Twenty microliters of bacterial culture were injected intratumorally. Mice were 
imaged as indicated using an IVIS 100 imaging system (acquisition time, 180 or 60 sec; binning, 
8; filter, open; f stop, 1; FOV, 25 cm). Photon flux data were calculated by utilizing software-
determined regions of interest (ROIs) around bioluminescent tumors with Living Image 
software.  
Tumor ex vivo imaging   
6-week old nu/nu mice (Taconic) were injected subcutaneously in the right flank with 1 x10
5
 
B16F10 cells and tumors allowed to grow for two and a half weeks. Saturated cultures of 
bacteria were diluted and 5 x10
5
 bacteria (based on OD600 readings) were injected intratumorally. 
At 24 and 48 hours following bacterial injections, mice were sacrificed, and tumors excised and 
dissected into 4 sections each. The bacterial-colonized tumor sections were incubated in 
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HEPES/Tris-buffered media at the indicated pH values and imaged using an IVIS 100 imaging 
system at the indicated times (acquisition time, 180 sec; binning, 8; filter, open; f stop, 1; FOV, 
12 cm).  
In vitro toxicity assays  
Confluent HeLa cells or mock media alone (DMEM + 10% FBS) were inoculated at 1:100 with a 
stationary culture of SB300A1 transformed with P1787 or P1787-Stx2A/B and cultured at 37 ⁰C 
for 18 hours. The cultured media was then separately filtered through a 0.22 μm filter to remove 
the bacteria and subsequently aliquoted at various volumes onto HeLa
CMV-FLuc
 cells pre-plated in 
a 96 well plate in quintuplicate.  24 hours later, bioluminescence of the conditioned media-
treated HeLa
CMV-FLuc
 cells was imaged using an IVIS 100. Phase contrast microscopy (TMS-F, 
Nikon) was used in parallel to qualitatively confirm loss of cell viability. 
In vivo toxicity assays  
6 week old male homozygous CrTac:NCr-Foxn1
nu
 mice (Taconic) were subcutaneously injected 
in the right flank with of 4.5 x 10
6
 HeLa
CMV-FLuc
 cells in 20 μL DMEM.  When tumor volumes 
reached approximately 100 mm
2
 (5 days later), mice were injected i.p. with 150mg/ kg of D-
luciferin and 10 minutes  later imaged using an IVIS 100. Immediately following imaging, mice 
were injected intratumorly with LB broth, or SB300A1 transformed with P1787, or SB300A1 
transformed with P1787-STx2A/B at either 2.5 x10
5
 (low-dose) or 2 x 10
6
 (high-dose) CFU/ 
injection.  Mice (n= 9-14 in each group) were weighed and imaged for bioluminescence every 
five days for 2 weeks. Viable tumor mass is presented as fold-initial photon flux (pre-treatment/ 
post-treatment). 
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Histology 
Tumors were excised and immediately frozen at -80°C. Frozen tumors were fixed in 10% neutral 
buffered formalin for 24 hours. Prior to paraffin embedding, histology sectioning and H&E 
staining, fixed tumors were washed with 30%, 50% and then 70% ethanol for 5 minutes each.  
Statistics: Error bars represent the standard error of the linearly regressed data or the standard 
error of the mean where noted.  
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B.4 Figures 
 
 
Figure 1. Design and utilization of a high throughput screen to identify tumor cell-induced 
gene activation events in Salmonella. (A) A schematic of the promoter trap system using Tn5-
based luxAB chromosomal integration. Expression of the promoterless luxAB reporter vector, and 
resulting Salmonella bioluminescence, is dependent on “trapping” an active promoter upstream 
of the chromosomal integration site. The transposon was randomly integrated into strain 
SB300A1, and kanamycin-resistant colonies were selected and arrayed into 96-well plates for 
library screening. Continued on next page 
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Representative primary screening plates in triplicate show responses of Salmonella library strains 
to three separate co-culture conditions: media alone (top), B16F10 melanoma cells (bottom left), 
HCT116 colon carcinoma cells (bottom right). Hit 47.74, showing selective activation in co-
culture with cancer cells, is indicated by the black open arrowhead, while the signals in the upper 
and central wells represent non-selective activation of clones. In each plate, wells H10, H11, and 
H12 (red box) contain media and bacteria constitutively expressing luxCDABE, bacteria 
constitutively expressing luxAB, and no bacteria, respectively, as controls. Primary library 
screening data from Salmonella promoter trap clones co-cultured with B16F10 melanoma cells 
(B) or HCT116 colon carcinoma cells (C). Data are reported as the log2 of the normalized signal 
for each library clone, where normalized signal was the ratio of the signal in the condition of 
interest to the signal in media alone. 
 
 
 
 
 
 
 
 
 
156 
  
 
Figure 2. Verification of Salmonella gene activation events in the context of tumor cell co-
culture. (A) Salmonella reporter clones displaying gene activation signals during co-culture with 
tumor cell lines (black bars, B16F10 cells; open bars, HCT116 cells). Salmonella strains luxAB 
and Tn:27.8 contain chromosomal luxAB genes under constitutive promoter control; luxCDABE 
Salmonella contain the full luciferase operon inserted into the chromosome; pMAAC001 
constitutively expresses plasmid-encoded luxCDABE. (B, C) Salmonella reporter clones display 
dose-responsive gene activation in co-culture with B16F10 and HCT116 cells. Bacteria were co-
cultured with 1x10
5
, 2x10
5
, or 3x10
5 
B16F10 or HCT116 cells/well. Data were normalized as the 
ratio of the signal in the condition of interest to signal in media alone. (Continued on next page) 
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Error bars correspond to SEM. All p value calculations are between luxCDABE and the group 
indicated by the symbol: * p ≤ 1x10-7; xp ≤ 0.06. (D) Semi-quantitative reverse transcriptase PCR 
with wild-type SB300A1 bacteria verifies that genes identified by the reporter transposon screen 
in Salmonella are activated during co-culture with B16F10 melanoma and HeLa tumor cells. 
rrsH = ribosomal RNA. 
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Figure 3. Acidic pH specifically and reversibly stimulates the Tn:1787 trapped promoter. 
(A) Bacteria were cultured in media of different pH values and reporter activation by Salmonella 
library clones in low pH media (pH 6) were compared to reporter activation in normal pH (7.5). 
Genes identified in the tumor cell co-culture screen were activated in the context of acidic pH 
compared to pH 7.5. pMAAC001 and luxCDABE constitutively express plasmid-encoded and 
chromosomally-encoded luxCDABE, respectively. Data were normalized as the ratio of the 
signal in media pH 6.0 to signal in media pH 7.5. Error bars correspond to standard error. 
(Continued on next page) 
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The data show one representative experiment with 4 replicates per condition tested. All p-value 
calculations are between luxCDABE and the group indicated by the asterisk, *p ≤ 2x10-14. (B) 
Mice bearing B16F10 flank tumor xenografts were injected intratumorally with tumor-activated 
(Tn:1787+pluxCDE) or constitutively bioluminescent (Tn:27.8+pluxCDE) Salmonella. The 
excised tumors were imaged hourly and data are presented as the normalized signal at each time 
point. The normalized signal represents the ratio of the mean of the fold-initial signal of two 
Tn:1787+pluxCDE-colonized tumors to the mean of the fold-initial signal of two constitutive 
Tn:27.8+pluxCDE-colonized tumors. The data presented are from a representative experiment; 
the experiment was performed independently two times, each with two mice per bacterial 
treatment group. (C) Representative ex vivo tumor imaging shows reversibility of the 
bioluminescent signal in the tumor-activated Salmonella. Images on the left show Salmonella-
infected tumor explants after 6 hours of incubation at the indicated pH (pH 6.0, top; pH 7.5, 
bottom). Two hours later (8 hours total), media was removed and replaced with media of the 
indicated pH (pH 7.5, top; pH 6.0, bottom). Images on the right show Salmonella-infected tumor 
explants 4 hours after the pH of the media was changed. 
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Figure 4. The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor 
microenvironment. (A) A representative mouse with two HCT116 flank tumor xenografts. The 
left tumor (black arrow) was injected with STM1787 pPROMOTERLux-expressing Salmonella, 
while the right tumor (red arrow) was injected with constitutive pMAAC001-expressing 
Salmonella, and the mouse imaged at the indicated times post-injection. (B) The mean photon 
flux for each set of Salmonella-injected tumors, normalized to the initial signal in each tumor, 
plotted as a function of time. Error bars represent SEM; pPROMOTERLux (n=6); pLux (n=3); 
pMAAC001 (n=3), *p<0.025 
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Figure 5.  P1787-driven Stx2 cytoxicity is selectively activated by the cancer cell 
environment in vitro. (A) Representative brightfield microscopy of HeLa
CMV-FLuc
 cells treated 
with 4 different conditioned, filtered media for 24 hours (+media+P1787; +media+P1787-Stx2; 
+HeLa+P1787; and +HeLa+P1787-Stx2). (Continued on next page) 
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Note the dramatic membrane blebbing and apoptotic morphology of +HeLa+P1787-Stx2 
conditioned media-treated cells. (B) Bioluminescence imaging of HeLa
CMV-FLuc
 cells treated with 
increasing amounts of 4 different conditioned, filtered media for 24 hours (bar groups, left to 
right: 17%, 29%, 44% of total volume per well). *p<0.0005 compared to all other treatments. 
Inset represents PCR amplification of Stx2A/B mRNA from P1787-Stx2 transformed SB300A1 
co-cultured with HeLa cells. 
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Figure 6. Enhanced anti-tumor response with P1787-Stx2 in vivo. (A) Viable cell mass of 
HeLa
CMV-FLuc 
tumors from mice treated with LB (n = 14), or high-dose SB300A1 transformed 
with P1787 (n= 12) or P1787-Stx2 (n = 9) at five days post treatment. Results are combined from 
two independent experiments and presented as fold-initial photon flux. Dotted line demarks lack 
of fold-change in tumor bioluminescence.  Error bars indicate standard error of the mean 
***p<0.0002,**p<0.0003, *p<0.007). (B) Fold-initialized photon flux of HeLa
CMV-FLuc 
tumors 
from mice treated with low-dose SB300A1 transformed with P1787 (n= 7) or P1787-Stx2 (n = 7) 
at 14 days post treatment. Error bars indicate standard error of the mean.*p <0.04. (C) H&E 
staining of HeLa
CMV-FLuc  
tumors from mice treated with LB (left), or high-dose SB300A1 
transformed with P1787 (middle) or SB300A1 transformed with P1787-Stx2 (right) after five 
days. Regions of tumor are denoted as tumor (T), fibroinflammatory reaction (I), and necrotic 
zone (N). Scale bar, 500 µm.  
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B.5 Table 
Table 1. Transposon chromosomal insertion locations in Salmonella reporter mutants. 
Strain Name Transposon Insertion 
Location 
Base pairs 
Downstream of 
Start Codon 
Function 
(Putative) (17)  
Tn:1787 STM1787  1,189  Hydrogenase 
Tn:1791 STM1791  505  Hydrogenase 
Tn:1793 STM1793  661  Cytochrome 
oxidase 
Tn:adiY adiY  439  araC-like 
transcriptional 
activator; 
arginine-
dependent acid 
tolerance 
Tn:yohJ yohJ  205  Hypothetical 
membrane protein 
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B.6 Supplementary Figure 
 
Supplemental Figure 1. Activated genes are not essential for Salmonella tumor localization. 
Mice bearing B16F10 flank tumor xenografts were injected intravenously with constitutively 
bioluminescent gene-deleted Salmonella. (A) Representative mice on day 10 post Salmonella 
injection. (B) Bioluminescent photon flux of the four mice depicted in (A) as a function of time 
following intravenous injection of bacteria. 
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B.7 Supplementary Table 
  
Supplementary Table I. Tumor localization of constitutively bioluminescent Salmonella 
mutants. 
Mutant Number of Mice with 
Bioluminescent, Colonized 
Tumors/Total Mice Injected 
(HCT116 Tumors) 
Number of Mice with 
Bioluminescent, Colonized 
Tumors/Total Mice Injected 
(B16F10 Tumors) 
Totals 
luxCDABE 2/3 3/4 5/7 
STM1789-1793 2/3 2/5 4/8 
adi 1/2 4/5 5/7 
yohJ 3/3 3/5 6/8 
 
 
 
